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  Scientists at Yale and around the world are 
challenging the laws of physics as they seek  
   new ways to peer ever more deeply into  
  the workings of the human body.
imag(in)ing
ON THE COVER Fluores-
cent dyes and confocal 
microscopy produced 
this image of brown 
adipose tissue (BAT), also 
known as brown fat, 
one of two types of fat 
tissues found in mam-
mals. BAT burns lipids (a 
group of molecules that 
include fats) in order to 
generate heat. The tissue 
was stained with dyes 
that bind either to lipids, 
which appear green in 
the image; or to the en-
dothelial cells that make 
up blood vessels and 
appear red. The stained 
tissues were imaged 
using fluorescent confo-
cal microscopy, which 
detects the fluorescent 
dyes individually. In the 
final stage, the images of 
each dye were merged 
to create this composite. 
Staining and confocal 
microscopy are among 
the key tools used by 
Yale scientists as they 
seek ways to look ever 
more deeply into the hu-
man body.
INSIDE COVER A similar 
process involving fluo-
rescent dyes and confo-
cal microscopy produced 
this image of white 
adipose tissue (WAT), 
commonly known as fat 
tissue. WAT is the major 
repository for lipids in the 
body and requires high 
vascularization, shown in 
red dye, in order to take 
up lipids from the blood 
after a meal.
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How to reach us
Yale Medicine welcomes news and com-
mentary. Please send letters (350 words or 
fewer) and news items to Yale Medicine, 1 
Church Street, Suite 300, New Haven, CT 
06510, or via e-mail to ymm@yale.edu, and 
include a telephone number. Submissions 
may be edited for length and content.
A new vision for Yale Medicine
The magazine in your hands or on 
your computer screen or tablet is 
the first that reflects a new design 
and vision for Yale Medicine. As 
we announced in our Spring 
issue, in addition to a redesign 
of the magazine, we focus our 
feature stories on a single topic 
in medicine, science, or medical 
education. The theme for this 
inaugural issue is biomedical 
imaging, in which we explore the 
ways in which biologists have 
endeavored to peer ever more 
closely at the molecular under-
pinnings of life. You can also visit 
our website at yalemedicine.yale.
edu, or download an iPad version 
at yalemedicine.yale.edu/app or 
by scanning the QR code at right. 




We would like to offer our 
thanks to these faculty and 
alumni who have served on the 
Yale Medicine Advisory Board for 
their counsel and insights over 
the past few years. We have 
benefited greatly from their 
participation in the planning of 
the magazine:
Sharon L. Bonney, M.D. ’76;  
Irwin M. Braverman, M.D.’55, 
HS ’56; Sharon A. Chekijian, 
M.D. ’01; John A. Elefteriades, 
M.D.’76, HS ’81, FW ’83; Rupali 
Gandhi, J.D. ’00, M.D.’04;  
Owen D. Garrick, M.D.’96;  
Robert H. Gifford, M.D., HS ’67;  
Elliott Levy, M.D. ’87; Raymond 
J. Lynch, M.D. ’05; Kavita 
Mariwalla, M.D. ’04; Bruce 
L. McClennan, M.D.; Gregory 
S. Raskin, M.D. ’98; Asghar 
Rastegar, M.D.; Lisa Sanders, 
M.D. ’97, HS ’00; Vinita Takiar, 
M.D. ’10, Ph.D. ’10; Karl G. 
Wagner Jr., PA-C ’90; and 
Warren D. Widmann, M.D. ’61, 
HS ’67. And we offer a special 
thanks to Michael Kashgarian, 
M.D. ’58, HS ’61, FW ’65, for his 
service as editor-in-chief of Yale 
Medicine, which began in 1986.
S E C ON D OPI N ION 
BY S I D N E Y H A RRIS
yalemedicine.yale.edu2
from the editor
When we talk about imaging at Yale School of Medicine, what does 
that encompass? Imaging includes everything from crystal-
lography to microscopy at the highest resolution, to X-rays, CT 
scans, MR, SPECT, and PET. It’s any technology that allows us 
to visualize biologically relevant structures and processes.
Why is it important? A rate-limiting factor in science now is 
access to the latest technology. For instance, our ability to under-
stand how the brain functions is presently limited by the avail-
ability of technologies that allow us to measure the function of 
individual neurons, parts of neurons, and even molecules within 
each specific neuron. Traditionally, the best medical schools 
invest in the best scientific talent and then equip those indi-
viduals with the best available technology. We’re investing in a 
third element, which is research in new technologies, so we can 
advance the state of the art. We want our scientists to invent the 
new technologies, which is already happening. 
How will imaging change science and medicine in the future? One 
way is the example that I alluded to earlier. I think the functional 
definition of all the circuits in the brain will come only from 
improved technologies in brain imaging. Another area where 
it might help is the use of imaging to identify new biomarkers. 
For instance, right now we’re very good at using imaging to see 
if someone has prostate cancer.  But can we tell if the prostate 
cancer is the type that needs to be taken out because it’s going 
to metastasize? Or if it’s the one that’s going to sit there and not 
metastasize? If you combined spectroscopy with imaging, by 
studying the metabolism of those cells, could you find something 
that determines whether they’ll metastasize? If you could, you 
would spare many patients unnecessary treatment, and you 
would lower health care costs at the same time. These are ben-
efits that would accrue across medicine and science.
T H I S I S S U E OF YA L E M E DIC I N E is devoted to bioimag-
ing technology. In our feature section we explore the his-
tory of biomedical imaging and examine how scientists at 
Yale are developing new ways of seeing smaller and smaller 
structures. Advances in imaging technology over the last 
several decades have enabled an ever more detailed view of 
the internal structures of organisms as well as their functions, 
from the level of molecules and cells to that of tissues, organs, 
and body. The pace of technological development is rapidly 
increasing, with the result that we can now see, in high reso-
lution, things that we could only guess at before. Below, Dean 
Robert J. Alpern, M.D., discusses the importance of imaging 













“I have gotten close to 1,000 
e-mails,” said Rothman, the 
Fergus F. Wallace Professor of 
Biomedical Sciences and professor 
and chair of cell biology, speak-
ing at a reception in the Beinecke 
Rare Book and Manuscript Library 
on the evening of October 7.  
“You hear from all kinds of peo-
ple: someone who practiced 
medicine with my father, a third 
grade classmate.”
Earlier in the day at a press 
conference he said he was still 
absorbing the news. “It’s a little 
hard to believe all this is happen-
ing,” he said. Rothman noted his 
good fortune in having studied at 
Yale and learning “to appreciate 
science and intellectual activity 
at its highest, to have matured 
and started my career as a 
researcher when your idea was 
the only limit. Any risk could be 
A S H E N E A R E D T H E E N D of the day in October 
that began with an early-morning phone call from 
Sweden, James E. Rothman, Ph.D., recalled before 
a gathering of his colleagues, students, and uni-
versity leaders what he described as an “out-of-
body experience”—the news that he had shared in 
the 2013 Nobel Prize in physiology or medicine.
  A Nobel Prize for  
 studies of cell trafficking
»
taken, no matter how difficult. I 
was fortunate to have taken a few 
of those risks and today’s Nobel 
Prize recognizes the success that 
came out of that.”
The prize acknowledged his 
contributions to the understand-
ing of membrane trafficking, 
the means by which proteins 
and other materials are trans-
ported within and between cells. 
Rothman, a 1971 Yale College 
graduate who previously shared 
in the Albert Lasker Award for 
Basic Medical Research, the 
Louise Gross Horwitz Prize of 
Columbia University, and the 
Kavli Prize in Neuroscience, is 
one of the world’s foremost 
experts on exocytosis, a form  
of trafficking in which cargo-
bearing spheres called vesicles 
fuse with cell membranes to 
deliver their contents.
CLOCKWISE FROM TOP LEFT
Dean Robert Alpern and 
President Peter Salovey 
praised Nobel laure-
ate James Rothman’s 
persistence in pursuing 
research into vesicles 
that transport material 
between and within cells.
At a press conference 
in the Historical Library, 
James Rothman, shown 
with his wife, Joy Hirsch, 
described receiving the 
news that he had won  
a Nobel as an “out-of-
body experience.”
Rothman told assembled 
journalists that vesicle 
trafficking is essential to 
many biological process-
es, including cell division 
and insulin secretion.  
It is also important in  
the nervous system, 
passing on messages 






















































This process is essential to 
such processes as cell division and 
insulin secretion, for example, 
but also plays a crucial role in the 
nervous system. Vesicles carry-
ing neurotransmitters fuse with 
cell membranes at synapses and 
pass on chemical messages that 
govern movement, perception, 
cognition, memory, and mood. 
For three decades, Rothman has 
performed experiments that have 
revealed the molecular machin-
ery of membrane trafficking in 
fine detail. In much of his work 
Rothman sidestepped the com-
plexities of working with com-
plete cells by using a “cell-free” 
approach—isolating the intracel-
lular components crucial to mem-
brane trafficking.
Rothman and the two scien-
tists who shared in the $1.2 mil-
lion award—Randy W. Schekman, 
Ph.D., of the University of 
California−Berkeley, and Thomas 
Südhof, M.D., of Stanford 
University—all faced skepticism 
within the scientific community 
when they began their research. 
Each went on to solve a different 
piece of the puzzle.
While Rothman figured 
out the machinery under-
lying membrane trafficking, 
Schekman discovered a set of 
genes essential for vesicle traf-
fic, and Südhof determined  
how vesicles know when and 
where to release their cargo.
Rothman began his research 
career after receiving his Ph.D. 
from Harvard in 1976. From there 
he went on to the Massachusetts 
Institute of Technology, Stanford, 
Princeton, Memorial Sloan-
Kettering, and Columbia before 
coming to Yale in 2008.
“When Jim started his career,  
a number of successful bio-
chemists were recognizing the 
importance of studying molecular 
processes in cell-free systems, 
but no one imagined that you 
could study vesicle trafficking in 
a cell-free system,” said Robert 
J. Alpern, M.D., dean and Ensign 
Professor of Medicine, at the press 
conference. This bold approach 
revolutionized the field.”
“Yale is absolutely thrilled 
to have one of our most distin-
guished faculty—who is also 
one of our most distinguished 
alumni—receive this great 
honor,” said President Peter 
Salovey, Ph.D., the Chris Argyris 
Professor of Psychology. 
— Charles Gershman  
and John Curtis
George E. Palade, Ph.D.,  
who served on the Yale  
faculty from 1973 to 
1990, and was the first 
chair of cell biology, 
shared the 1974 Nobel 
Prize in physiology or 
medicine with Albert 
Claude, Ph.D., and 
Christian de Duve, Ph.D. 
The prize was granted 
for “for their discov-
eries concerning the 
structural and functional 
organization of the cell.” 
Palade’s innovations in 
electron microscopy 
laid the foundations of 
modern cell biology.
Sidney Altman, Ph.D., 
Sterling Professor of 
Molecular, Cellular, 
and Developmental 
Biology and professor 
of chemistry, shared 
the 1989 Nobel Prize in 
chemistry with Thomas 
R. Cech, Ph.D., “for their 
discovery of catalytic 
properties of RNA.”
Thomas A. Steitz, Ph.D., 
Sterling Professor of Mo-
lecular Biophysics and 
Biochemistry, professor 
of chemistry, and inves-
tigator, Howard Hughes 
Medical Institute, shared 
the 2009 Nobel Prize in 
chemistry with Venka-
traman Ramakrishnan, 
Ph.D., and Ada E. Yonath, 
Ph.D., “for studies of the 




Yale celebrates its  
23rd president
In his more than 30 years at Yale, 
Peter Salovey, Ph.D. ’86, has been 
a student, scholar, psychologist, 
and scientist. Over those years he 
has risen through the university 
hierarchy—serving as chair of 
psychology, Yale College dean, 
provost, and now, president.
His tenure became official on 
October 13 with his inaugura-
tion as Yale’s 23rd president. In 
the week leading up to the cer-
emony, Yale celebrated with a 
reception for faculty and staff, 
a parade of dogs including Yale 
mascot Handsome Dan, an open 
house, and a panel of university 
presidents who offered their 
cumulative wisdom. Salovey, 
the Chris Argyris Professor of 
Psychology, also visited 27 schools 
and departments across Yale. His 
penultimate visit brought him to 
the medical school, where he has 
longstanding collaborations in 
research in cancer and HIV/AIDS. 
As a social psychologist, he is best 
known for developing the concept 
of emotional intelligence with 
colleague John D. Mayer, Ph.D.
The roles he has filled 
throughout the university have 
given him a sense of commu-
nity that infused his inaugural 
address, in which he vowed to 
continue to “bring Yale to the 
world and the world to Yale.” 
On the stage in Woolsey Hall, 
flanked by his predecessor 
Richard C. Levin and dignitaries 
including New Haven Mayor John 
DeStefano Jr., Salovey noted the 
achievements of Levin’s 20-year 
tenure. Many reflect engagement 
with the broader world: a strong 
partnership with the city of New 
Haven, more than 900 faculty 
members engaged in overseas 
projects, and Yale’s emerging sta-
tus as a global institution.
Salovey said that he would 
develop a university that is both 
more unified and more global and 
ensure that Yale remains acces-
sible to “brilliant, hard-working, 
and committed applicants who 
would invigorate our campus 
and improve our world.” He 
promised to “support, expand, 
yalemedicine.yale.edu6
chronicle
good news to share: Robert J. 
Shiller, Ph.D., Sterling Professor 
of Economics, had won the Nobel 
Prize in economic science.)
But being part of a larger 
community allowed him to birg, 
a term from social psychology 
that stands for bask in reflected 
glory. “You identify with some-
thing bigger than yourself, like 
Yale; then, when something 
good happens to someone else 
in that organization, your self-
esteem goes up. Jim Rothman 
won the Nobel Prize—that 
reflects on me!” Salovey said.  
“If you can identify with some-
thing bigger than yourself and 
‘bask in reflected glory,’ you 
can feel pretty good about other 
people’s successes. This is the 
key to happiness. … This is what 
makes this place so wonderful.”
—John Curtis
»
How Cold War nuclear  
testing launched the field  
of DNA repair at Yale
In the 1950s, U.S. Senator 
Prescott Bush, a Republican 
from Connecticut and father and 
grandfather to future presidents, 
approached Yale’s biophysics 
faculty with a request. Could 
they determine whether radia-
tion causes irreparable damage 
to human DNA?
World War II had just ended 
with the first strategic use of 
atomic weapons. The Soviet 
Union and the United States were 
locked in a Cold War arms race. 
Scientists and the public alike 
feared that radiation from nuclear 
testing would cause irreparable 
DNA damage and cancer—a belief 
that grew out of the illness and 
death in the aftermath of the 
atomic bomb blasts in Japan.
The Atomic Energy Commission 
(AEC) countered that people 
exposed to equivalent doses of 
radiation exhibited different out-
comes; while some developed 
cancers, others didn’t. It was 
premature, the AEC concluded, 
to say that the effects of radiation 
were irreversible.
The search for answers was 
on. Yale biophysics and radio-
biology researchers began to 
study the effects of radiation on 
living cells. “The time was ripe 
and the situation was ideal,” 
recalled Philip Hanawalt, Ph.D. 
’59, then a graduate student 
in the biophysics department. 
“Watson and Crick had just 
reported the structure of DNA, 
and celebrate basic and problem-
driven research in the fields of 
today and those of tomorrow.
“Our task,” he said, “even 
while we grow in size, even 
while we commit to being a 
more diverse faculty, staff, and 
student body; more cross dis-
ciplinary; and more global, is 
to retain Yale’s focus on the ties 
that bind us together, the sense 
of being a small, interdependent 
community, but one with an 
impressively broad scope. This 
intimacy and shared sense of 
purpose is what generates Yale’s 
distinctive spirit.”
Glad tidings added to that 
sense of unity in the days lead-
ing up to his inauguration: A 
1954 Yale College alumnus gave 
Yale College the largest gift in 
its history—$250 million; James 
Rothman, Ph.D., chair of cell 
biology and an alumnus of Yale 
College, shared in the 2013 Nobel 
Prize in physiology or medicine, 
and the football team kicked 
off the season with a 3-0 win-
ning streak. (The day after his 
inauguration Salovey had more 
Yale’s new president, 
Peter Salovey, greeted 
well-wishers during a 
procession from Woolsey 
Hall to a block party on 
Hillhouse Avenue. The 
university’s task, he said 
in his inaugural address, 
is to “retain the ties that 















Med school alum nomi-
nated as surgeon general.
Med student’s research 
recognized at a cancer 
conference.
A lesson from a Nobel 
laureate.
How the medical school 
is recruiting minority 
faculty.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 
on our homepage at 
yalemedicine.yale.edu.
and biophysicists at Yale decided 
it was important to learn what 
radiation did to DNA.”
Hanawalt and other re-
searchers reflected upon those 
heady times in May, when the 
Department of Therapeutic 
Radiology hosted a symposium 
to commemorate 50 years of 
DNA repair research at Yale.
Hanawalt, who holds the Dr. 
Morris Herzstein Professorship 
in Biology at Stanford, recalled 
an all-hands-on-deck mentality 
among the biophysics faculty.  
“We met weekly for informal 
research discussions. We were like 
a large family sitting around the 
table discussing science. We were 
all focused on a common goal, 
figuring out what radiation did to 
cells, and particularly to DNA.”
In their search for answers 
Yale scientists made many of the 
pioneering discoveries in the 
field of DNA repair. Researchers 
in the Radiology Department, a 
precursor to the Department of 
Therapeutic Radiology, and in 
biophysics discovered not only 
DNA repair mechanisms but 
also their genetic control. The 
research that began at Yale led, 
Hanawalt said, “to an under-
standing of the multiple DNA 
repair mechanisms required for 
the maintenance of genomic sta-
bility in all living cells.”
The formal discovery of DNA 
repair occurred in three labora-
tories simultaneously. Hanawalt’s 
graduate research with Richard 
Setlow, Ph.D. ’47, initiated studies 
on the inhibition and recovery of 
DNA synthesis in bacteria follow-
ing irradiation with ultraviolet 
light. Then Setlow subsequently 
found, mutant cells that were 
sensitive to ultraviolet light 
retained damage in their DNA, 
while normal cells cut out the 
damage. Hanawalt had moved 
to Stanford, where he showed 
that repair patches were inserted 
into DNA, presumably replacing 
the damaged parts that had been 
removed. At Yale, Paul Howard-
Flanders, Ph.D., isolated mutant 
bacteria sensitive to ultraviolet 
light and reported that while nor-
mal bacteria removed the damage, 
the mutant bacteria could not. 
Damage in DNA, the researchers 
concluded, can be cut out and the 
missing parts replaced correctly 
through a process called nucleo-
tide excision repair.
Joann Sweasy, Ph.D., profes-
sor of therapeutic radiology and 
of genetics, pointed out that 
DNA repair occurs naturally in 
our cells every day. “But if the 
repair isn’t good, or there’s a 
faulty gene, that’s when you get 
suboptimal mutations that lead 
to cancer,” she said.
Peter Glazer, M.D. ’87, 
Ph.D. ’87, chair and Robert E. 
Hunter Professor of Therapeutic 
Radiology, professor of genet-
ics, and member of the faculty 
advisory committee of the Cancer 
Biology Institute at West Campus, 
has overseen a $9 million grant 
from the National Cancer Institute 
titled “DNA repair in cancer biol-
ogy and therapy.” The title sug-
gests an important goal for the 
field of DNA repair. The grant, 
which ended June 30, was to take 
advantage of knowledge of DNA 
repair pathways in order to treat 
cancer. The interdisciplinary 
effort brought together more than 
a dozen investigators to focus on 
fundamental and translational 
cancer biology.
“The DNA repair field is get-
ting more and more exciting 
in its complexity and its rel-
evance to human health,” said 
Hanawalt. “If you Google DNA 
repair, you’ll get more than 
18 million hits. It’s alive and 
well, and the early insights of 
radiation biologists at Yale got it 
started, while current scientists 





About a quarter of those who 
have survived melanoma 
leave the sunscreen at home 
on sunny days, and some sur-
vivors still use tanning beds, 
according to research by Yale 
Cancer Center (YCC) that was 
presented at the American 
Association for Cancer 
Research Annual Meeting 
2013 in Washington, D.C. Both 
tanning beds and unpro-
tected sun exposure raise the 
risk of life-threatening skin 
cancer. Using data from the 
National Health Interview 
Survey, conducted annually 
by the Centers for Disease 
Control and Prevention, the 
Yale team found that most 
of a sample of 171 melanoma 
survivors were taking pre-
cautions, but 15.4 percent 
said that they rarely or 
never stay in the shade; 
27.3 percent said that they 
never wear sunscreen when 
they’re outside on sunny days 
for more than an hour; and 
2.1 percent reported using an 
indoor tanning bed during the 
previous year. “It’s incredibly 
disturbing that even after 
getting the disease once, 
some survivors continue 
these practices, which would 
put them at greater risk of 
getting it again,” said author 
Anees B. Chagpar, M.D., 
M.P.H., associate professor of 
surgical oncology at YCC and 
director of the Breast Center 
at Smilow Cancer Hospital at 
Yale-New Haven.
MELANOMA SURVIVORS USING TANNING BEDS
CANCER PATIENTS: QUIT SMOKING
It may seem like a no-brainer, 
but Yale Cancer Center ex- 
perts and the American Asso-
ciation for Cancer Research 
(AACR) are calling on doctors 
to advise their patients to quit 
smoking after being diag-
nosed with cancer—any can-
cer. Patients who smoke have 
worse outcomes than those 
who quit, and quitting smok-
ing improves the efficacy of  
cancer treatments, reduces 
risk for future cancers, and 
enhances rates of survival. 
This is true for many cancers, 
not just lung cancer. The 
experts made their call in a 
statement released at the 
AACR Annual Meeting 2013 in 
Washington, D.C. “It is crucial 
that all oncologists in any 
setting both assess tobacco 
use and take ownership of 
ensuring that their patients 
receive appropriate treatment 
for their tobacco use,” said 
Benjamin A. Toll, Ph.D., asso-
ciate professor of psychiatry, 
director of the smoking ces-
sation program at Yale Cancer 
Center, and chair of the com-
mittee charged with writing 
the AACR policy statement.
INFLAMMATION  
& DISEASE
Everybody knows what hap-
pens when we get hurt or 
infected. The injured part 
of our body swells. That’s 
our innate immune system 
offering a short-term fix by 
attempting to restore the 
proper physiological balance. 
But that quick fix may also be 
a root cause of many serious 
disorders, according to Ruslan 
M. Medzhitov, Ph.D., and 
Richard A. Flavell, Ph.D. The 
two immunobiologists have 
proposed a unifying theory 
to describe how inflamma-
tion can affect the body’s 
homeostatic control mecha-
nisms to trigger the onset of 
disease. Now Medzhitov, the 
David W. Wallace Professor of 
Immunobiology and a Howard 
Hughes Medical Institute 
(HHMI) investigator, and Flavell, 
chair of the department of 
immunobiology, Sterling 
Professor of Immunobiology, 
and an HHMI investigator, will 
have a chance to test their 
theory of inflammation and 
chronic disease, thanks to 
a $10 million grant from the 
Blavatnik Family Foundation, 
the charitable organization 
headed by American indus-
trialist and philanthropist 
Len Blavatnik. The grant will 
support the scientists’ efforts 
to define the molecular links 
among inflammation, com-
mensal microorganisms, and 
chronic disease.
PATHWAY TO  
NEW ARTERIES
Scientists at the School of 
Medicine and University 
College London (UCL) have 
found a molecular pathway 
that can bypass blocked 
arteries and help form new 
arteries after heart attacks, 
strokes, and other acute ill-
nesses. The Yale-UCL team 
reported in the April 29 
issue of Developmental 
Cell that in order to make 
new arteries, which can 
form in adults when organs 
become oxygen-deprived, 
three molecules must work 
together. The oxygen-starved 
organs must first release a 
molecular signal called VEGF. 
That signal must then bind 
with two molecules known 
as VEGFR2 and NRP1. NRP1 
transports the other two 
molecules to a signaling 
center in the walls of blood 
vessels. Mice that lacked part 
of that transporter had poorly 
constructed arterial branches 
in their internal organs and 
could not repair blood ves-
sel blockage by forming new 
arteries. “This opens new 
therapeutic opportunities for 
developing drugs that would 
either stimulate or inhibit 
blood vessel formation,” said 
corresponding author Michael 
Simons, M.D. ’84, professor 
of medicine and cell biology, 
and director of the cardiovas-






















































































a collection of recent  
scientific findings
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/ 12 From dead cells to live movies / 22 Can brain scans reveal how we think?  / 33 Inside the toolbox / 36 A new vision in the lab and in the clinic
  Scientists at Yale and around the world are 
challenging the laws of physics as they seek  
   new ways to peer ever more deeply into  
  the workings of the human body.
SINCE THE IN VENTION OF THE MICROSCOPE  in the 1700s, scientists 
have struggled to find new ways to peer deeper and deeper into the human 
body to look at smaller and smaller cells and organelles. Constrained for 
centuries by a law of physics, they began to find ways to overcome what is 
known as the diffraction limit only in the 20th century. New technologies 
now allow scientists to see things on a scale once thought impossible, and 
the knowledge gleaned from those views is helping clinicians find new 
ways to care for patients. In this issue of Yale Medicine, we explore the 
ways in which Yale investigators and physicians are pushing the frontiers 
of imaging technology in a search for answers to human biology and dis-
ease. Our lead story by Ashley Taylor, “From dead cells to live movies,” 
looks at super-high-resolution microscopy, which has advanced cell biol-
ogy by offering real-time glimpses of what one scientist calls “cellular fire-
works.” John Dillon interviewed a neurosurgeon, a diagnostic radiologist, 
and a urologist who work with scientists to improve care for their patients 
through new imaging techniques. Jenny Blair delved into the debate in 
neuroscience over the mind and the brain: Can scientists determine your 
political, moral, or philosophical leanings based on an fMRI scan of your 
brain? And Amanda Alvarez described core imaging facilities at the School 
of Medicine that provide access to new technologies.
imag(in)ing
/ 12 From dead cells to live movies / 22 Can brain scans reveal how we think?  / 33 Inside the toolbox / 36 A new vision in the lab and in the clinic
“Valentine,” by Elizabeth Jameson, is a Solarplate 
etching on paper that shows a coronal view of her 
brain stem, cerebellum, and lateral ventricles. In 
her art, Jameson said in her artist’s statement, she 
celebrates the beauty, complexity, and mystery 
of the brains of individuals who, like herself, have 
one of the most common neurological diseases of 









































New light microscopes developed by Yale cell  
biologists are helping researchers unravel the  
complexities of human biology. 
By Ashley Taylor
New light microscopes developed by Yale cell  
biologists are helping researchers unravel the  
complexities of human biology. 
By Ashley Taylor
cargo, vesicles are recycled and take on more 
neurotransmitters for another shipment. 
When the protein dynamin is mutated, this 
recycling does not occur and vesicle buds 
(green) that cannot be released to generate 
new vesicles accumulate at the cell surface 
and its infoldings.
Pietro De Camilli, who studies how brain cells 
package neurotransmitters, used electron 
tomography to capture this 3-D image that 
shows what happens when the process goes 
awry. Vesicles about 40 nanometers in diam-
eter (blue) deliver neurotransmitters between 
cells by fusing with the outer membranes of 



























I N 1974,  T H E L AT E G E ORG E E .  PA L A DE , PH.D.,  chair of Yale’s newly formed 
cell biology department, shared a Nobel Prize in physiology or medicine for 
using electron microscopy to elucidate the inner workings of cells—ground-
breaking findings that some say ushered in the modern field of cell biology. 
But although the electron microscope opened new avenues of research, it 
had a huge drawback as a tool for studying life: it can observe cells only after 
they are dead, treated with special fixatives, and sliced into thin sections 
or coated in a layer of metal. The grayscale world pictured in such detail 
in electron micrographs, while powerful, is “a cellular cemetery,” in the 
words of Pietro De Camilli, M.D., FW ’79, the Eugene Higgins Professor of 
Cell Biology, professor of neurobiology, and director of the Yale Program in 
Cellular Neuroscience, Neurodegeneration and Repair.
Because electron microscopy’s vision is limited to dead 
cells, it provides just a snapshot of a cell’s inner work-
ings. Derek K. Toomre, Ph.D., associate professor of 
cell biology, likes to compare an electron micrograph of 
a cell to a still photograph taken during a football game. 
If you are trying to learn the rules of the game, Toomre 
said, a snapshot doesn’t get you very far. The same is 
true in biology. “There are a lot of biological problems 
that—if you could see them in living cells in action—we 
would be able to unravel.”
To observe live cells, scientists use light microscopy, 
which includes the dissecting microscopes familiar 
from high school biology and extends to high-tech 
microscopes whose images brighten the pages of scien-
tific journals.
But standard light microscopy too has a major 
limitation in resolution: scientists have known since 
the 19th century that it cannot resolve, or distinguish 
between, structures smaller than about the size of 
organelles. Smaller structures—the vesicles carrying 
cellular messages and the protein scaffolding that gives 
cells their heft and shape—blur together because of 
what is called the diffraction limit, described in 1873 
by Ernst K. Abbe, a contemporary of the microscope 
manufacturer Carl Zeiss.
A light microscope, even with an excellent lens, can-
not resolve structures smaller than about half the wave-
length of the light used to illuminate them. That works 
out to a resolution of about 250 nanometers, around the 
size of the measles virus and about 400 times smaller 
than the width of a strand of human hair.
In trying to learn the rules of cell biology’s game, 
scientists had at their disposal detailed still images 
from the electron microscope and views of the cell in 
action from the light microscope, with some of the 
most interesting players too small to see. Although 
each type of microscope had its uses, between them lay 
a large gap. 
In the last 20 years, however, scientists have found 
ways to overcome the diffraction limit and close that gap 
through what is called super-resolution light micros-
copy. Using custom-made fluorescence microscopes, 
some designed by Yale scientists, researchers at Yale are 
observing the live-cell dynamics of structures that they 
could previously see only in snapshots. With these new 
data, they are beginning to answer scientific questions 
nearly as old as the limit that once held them back.
“This is the direction in which we have to go,” said 
De Camilli, who studies how brain cells package 
neurotransmitters, the chemicals that pass along neu-
ronal signals. “Super-resolution microscopy is really 
the next critical step.” Gesturing toward a photo on 
his wall of a smiling Palade, who looks as though he’s 
listening in on our conversation, De Camilli continued, 
“Palade was a pioneer in the use of electron microscopy. 
We feel like super-resolution microscopy is the next 
frontier in microscopy, and we think it’s appropriate 
that it happen here, in the heritage of George Palade.”
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TOP “This is the direction in 
which we have to go,” said 
Pietro De Camilli. High- 
resolution imaging tech-
nologies can overcome the 
diffraction limit that held back 
advances in cell biology for 
many years. De Camilli, shown 
here with a TIRF microscope, 
uses the new imaging modali-
ties to study how brain cells 
package neurotransmitters.
MIDDLE Epifluorescence mi-
croscopy produced this image 
of synapsin (green spots on 
the surface of two neurons) 
and adaptin (in red). These two 
proteins play a role in forming 
and storing neurotransmitter-
filled synaptic vesicles at sites 
where neurons communi-
cate. Comparing the stain-
ing patterns of synapsin and 
alpha-adaptin—under different 
conditions of neuronal activity 
and/or after pharmacological 
and genetic perturbations—al-
lows researchers to assess the 
status of synaptic vesicles and 
their recycling. Shawn Ferguson, 
who produced this image, noted 
that it “does not boast a high 
degree of resolution—hundreds 
of nanometers.”
BOTTOM De Camilli and his 
collaborators used super-
resolution microscopy to 
create these images of vesicles 
being reformed. The color im-
ages show the location of two 
proteins, dynamin and clathrin, 
involved in that process. “We 
are zooming in at incredible 
levels of resolution,” he said. 
The color images were taken 
with fluorescence microscopy 
and the other image was taken 
with electron microscopy.
cellul ar f ireworks
Joerg Bewersdorf, Ph.D., assistant professor of cell biol-
ogy and of biomedical engineering, “stumbled into 
microscopy” in 1996. Then an undergraduate study-
ing physics at the University of Heidelberg, Bewersdorf 
wanted to develop technologies that would help scien-
tists in other fields. After taking an optics class with 
Stefan W. Hell, Ph.D., who, Bewersdorf said, was then “a 
junior professor, not really known, just a very dynamic 
person,” Bewersdorf joined Hell’s new lab at the Max 
Planck Institute for Biophysical Chemistry 
in Göttingen, which was quite small at 
the time. “Eight years later, when I left,” 
Bewersdorf remembers, “the lab had like 
35 people, Hell was famous and had won a 
lot of awards, and this whole field of super-
resolution microscopy had taken off.”
Hell, director of the institute since 2002, 
had broken the diffraction limit, build-
ing a microscope that allowed scientists to 
see tiny biological structures in a way not 
thought possible.  For years Abbe’s diffrac-
tion limit had been considered dogma, with 
scientists skeptical of attempts to bypass 
it, Bewersdorf said. Breaking the limit 
required a change in the way scientists 
thought about microscopy.
“To really break the diffraction limit, 
you can’t think of the microscope as just 
optics,” said Bewersdorf. “And this is 
what people had done for 150 years—it 
was always about lenses or it was always 
about light.” Instead, said Bewersdorf, Hell 
was thinking about the interaction of the 
microscope light with the cells or tissue being exam-
ined. Hell believed that resolution could be improved, 
not by modifying the light used to make a sample fluo-
resce but by altering the fluorescent light as it is emitted. 
Using this approach, Hell theorized in a visionary 1994 
paper in the journal Optics Letters that he would be able 
to achieve a resolution of 35 nanometers—small enough 
to see not just organelles but structures within them, 
like the involutions of the mitochondria, the cell’s power 
plants, or the many layers of the Golgi apparatus, the 
cell’s protein-processing pipeline.
By 1999, Hell had built a super-resolution micro-
scope. His new technique was called stimulated emission 
depletion (STED) microscopy. A year later his lab showed 
that STED could work with biological material. In 2006, 






































describing a different approach to light microscopy that 
achieved even higher resolution than Hell’s technique. 
Each group gave its version of the technique a different 
name: photoactivated localization microscopy (PALM); 
fluorescence photoactivated localization microscopy 
(fPALM); and stochastic optical reconstruction micros-
copy (STORM). All three versions, however, rely on the 
same principle—imaging a fluorescently labeled sample 
a few scattered points at a time. By 2012, scientists were 
using the term “diffraction-unlimited microscopy,” or 
even “nanoscopy,” to reflect the fact that these new 
microscopes work on the scale of nanometers. The para-
digm shift was complete.
At about the time that Hell was develop-
ing his new microscope, from 1997 to 2001, 
Toomre was also in Germany (though he did 
not meet Bewersdorf until they both came to 
Yale) as a postdoctoral fellow at Heidelberg’s 
European Molecular Biology Laboratory. 
Toomre was trying to learn about vesicles, the 
bubble-like structures that cells use to shuttle 
materials in and out and from one cellular 
location to another. Vesicles are ubiquitous 
in biology—they transport everything from 
hormones to neurotransmitters. In the brains 
of animals, signals pass from one neuron to 
another thanks to a process called exocy-
tosis, in which vesicles packed with neuro-
transmitters fuse with the cell membrane of 
one neuron and empty the chemicals into the 
synapse—the space between it and the next 
neuron—to transmit the message. (James 
E. Rothman, Ph.D., the Fergus F. Wallace 
Professor of Biomedical Sciences and professor 
and chair of cell biology, shared in the 2013 Nobel Prize 
for physiology or medicine for his studies of vesicles.)
“I was frustrated,” said Toomre, “because we knew 
biochemically that these things had to go out to the 
surface, and we could see these little vesicles mov-
ing, but we really didn’t see them fuse.” He had tried 
to simulate vesicle fusion in a test tube, an effort that 
failed after a year. But he had heard about a microscope 
called a total internal reflection fluorescence (TIRF) 
microscope that might help. The TIRF microscope 
could selectively illuminate objects in a thin 80- 
nanometer optical section and achieve much higher 
resolving power than traditional confocal microscopes 
—but only near the surface of the cell. The technology 
was perfect for observing the fusion of a vesicle with 
the cell membrane. Toomre “begged and pleaded” to 
TOP A split image of microtubule structures shows 
the advantage of a super-resolution pointillism 
technique called fPALM/STORM over traditional 
imaging methods. Thousands of images of fluo-
rescent molecules are taken and reassembled by 
computers. Microtubule structures are important in 
processes ranging from maintaining cell structure 
to providing platforms for intracellular transport.
ABOVE This is not your grandparent’s microscope. In 
their efforts to obtain images of smaller and smaller 
structures, scientists have moved away from lenses 
and light to such complex and sophisticated devices 
as this STED microscope, which relies on fluores-
cence and laser beams. Joerg Bewersdorf trained in 
physics, but now works with cell biologists looking 
















































































The period at the end of this sentence is 1 million 
nanometers wide. With super-resolution micros-
copy, scientists can see synaptic vesicles as small 
as 30 nanometers wide. Imagine taking a picture 
of the continental United States from the strato-
sphere and being able to distinguish a single strand 
of hair.
Fluorescent tags make this possible. Molecules 
and structures of interest are given a fluorescent 
tag—either a dye or a genetically engineered tag 
like green fluorescent protein (GFP). A laser beam is 
directed at the target sample, which makes the tag 
emit light, and the resulting fluorescence is recorded 
to create an image.
The first fluorescence microscopes scanned 
an entire sample at once, which produced a fair 
amount of out-of-focus fluorescence. Today’s stan-
dard fluorescence microscope—the confocal micro-
scope—scans a sample one point at a time, pixel by 
pixel, and assembles the pixels to create an image. 
The size of each fluorescent point in these standard 
microscopes is determined by how much the laser 
light diffracts and is limited by the diffraction limit 
to between 200 and 250 nanometers.
Stefan Hell’s innovation, STED, improves resolu-
tion by reducing the size of each fluorescent spot. 
STED targets the light returning from the sample 
and a second laser blocks out the fluorescence in a 
donut shape around the center of each fluorescent 
spot. Each fluorescent point is reduced to the size 
of the donut hole. These smaller points of light 
yield a higher-resolution image. STED microscopy 
can achieve a resolution of 25 to 80 nanometers, 
small enough to distinguish cellular vesicles and 
the folds within organelles.
PALM/fPALM/STORM capture just a few scat-
tered molecules at a time so that they are unlikely 
to overlap and blur together. Using labels that turn 
on and off, scientists arrange to have only a few 
molecules fluoresce at one time; then they take 
a picture. A computer finds the center of each 
spot, representing a single fluorescent molecule, 
on the individual photo. This process is repeated 
thousands of times, and the photos are then com-
bined. The approach is sometimes called pointillist 
microscopy, after Impressionist Georges Seurat’s 
painting technique. Pointillist techniques achieve 
extremely high resolution, about 25 nanome-
ters. However, the technique can also be slow—it 
requires many photos to generate one image, and 
it is dependent on high-powered computers to 
process the data.
TIRF microscopy, developed in the early 1980s, 
excites fluorescence in a thin layer near the cell 
surface, which reduces background fluorescence 
and improves resolution to between 40 and 100 
nanometers. TIRF microscopy is faster than poin-
tillist techniques but has lower resolution and can 
record only the cell surface.
These are only a few of the high-resolution 
microscopy techniques available today, and Yale is 
unusual in that it has all these microscopes—STED, 
PALM/fPALM/STORM, the electron microscope, 
and others—in one place, said Derek Toomre. Each 
has its strengths and weaknesses. “If we knew 
that there was one type that could do everything, 
we wouldn’t be investing in all of them. … There’s 
no clear winner. We’ll see; maybe there will be.”
Breaking the diffraction limit
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borrow the TIRF microscope in the lab of cell physi-
ologist Wolf Almers, Ph.D., who was then at the Max 
Planck Institute. “Within a few hours of imaging,” said 
Toomre, “we had an amazing result. We could see these 
vesicles arrive and explode during fusion.” In 2000, 
Toomre, Almers, and others published their observa-
tions in The Journal of Cell Biology. This was Toomre’s 
entrée into super-resolution microscopy, which he 
would pursue at Yale beginning in 2001.
In his office, Toomre shows a more recent video gen-
erated by a TIRF microscope of fluorescently labeled 
vesicles fusing with the cell membrane. Fluorescent 
green dots—the vesicles—move around on the screen, 
then flash brightly as they fuse with the cell membrane. 
“It’s fireworks,” Toomre said. “Cellular fireworks.”
new frontiers … in b iology
Bewersdorf, one of the first physicists recruited to the 
highly interdisciplinary Department of Cell Biology at 
Yale, joined the faculty in 2009 because he wanted to 
collaborate with biologists who were using these new 
microscopes to answer important questions in biology. 
A burning question both within and outside the 
department: How does the Golgi apparatus, the cell’s 
protein processing plant, work? A stack of membrane-
bound disks, the Golgi processes proteins into their final 
forms, adding sugar and phosphate molecules  as they 
pass from one end of the stack to the other and are sorted 
to other areas of the cell. If necessary, the Golgi packages 
them into vesicles to be released from the cell. For 100 
years, Toomre said, scientists have debated whether the 
Golgi is a stable structure that moves vesicles around or a 
dynamic structure that transforms itself into the vesicles 
it releases. The debate continues, as a major roadblock is 
the inability to see small vesicles trafficking within the 
highly convoluted Golgi “pancake” in live cells. Now, by 
labeling both the Golgi and the proteins moving through 
it, then watching the labeled cells at super-resolution, an 
international consortium of researchers at Yale, Oxford, 
and Cambridge are hoping to find the answer.
Vesicles are also a focus of De Camilli’s lab, which is 
studying the way they are made. Vesicles are formed 
by pinching off from a larger membrane, like the cell 
membrane or the membrane of an organelle. De Camilli 
wanted to know which proteins are responsible for 
cutting the new vesicle off from its parent membrane. 
Two proteins might be involved, he thought: clathrin 
and dynamin. He wanted to see where the two pro-
teins are located on the vesicle. In his office, De Camilli 
draws furiously on a scrap of paper: green for clathrin, 
Seeing the unseeable
Starting around the turn 
of the 17th century, natu-
ral philosophers using the 
light microscope saw 
things where, to the naked 
eye, there was nothing 
to see. The Englishman 
Robert Hooke observed 
pockets of air within cork, 
which he called cells; the 
Dutch scientist Anton van 
Leeuwenhoek saw living 
bacteria in pond water 
and cells within blood 
and even found “wee 
beasties,” as he sometimes called his “cavorting” 
specimens, in his own semen.
Electron microscope
In the 1930s, the German physi-
cist Ernst Ruska developed a 
microscope with ultra-high 
resolution by using electrons, 
which have a smaller wave-
length than light and can dis-
tinguish tinier features. Using 
Ruska’s new electron micro-
scope, scientists could view 
structures within an individual 
cell, with the downside that they 
could not look at live cells.
“Cavorting  
wee beasties”
The magnitude of advances in micros-














































TOP Throughout his career Derek Toomre has tried 
to learn more about vesicles, structures that move 
proteins, neurotransmitters, and other cargo in 
and out of cells and from one cellular location to 
another. This composite image, taken with dual-
color live-cell epifluorescence microscopy, shows 
vesicles moving along microtubule “highways.”
ABOVE Toomre believes that seeing cells in real 
time is crucial to understanding human biology. 
“There are a lot of biological problems that—if you 
could see them in living cells in action—we would 
be able to unravel.”
gray for dynamin. Under regular light microscopy, 
clathrin and dynamin seem to overlap. To demonstrate 
this overlap, De Camilli draws green and gray swirls, 
one atop the other. But using super-resolution micros-
copy, he shows me that dynamin is clearly distinguish-
able from clathrin.
 … in  medic ine …
The new information about cell structure revealed by 
super-resolution microscopy is helping scientists to 
understand the mechanisms of diseases that affect 
humans, De Camilli said—in particular, diseases rooted 
in genetic mutations. Many genetic disorders, he said, 
result from changes in the distribution or localization 
of proteins in cells. “In order to understand in which 
way the mutation affects cell function, it is very useful 
to be able to localize either the mutant protein itself or 
organelles and proteins with which it interacts or the 
organelle on which it is localized,” De Camilli said.
For example, De Camilli is studying Lowe syndrome, 
a rare disorder that almost exclusively affects males and 
causes intellectual disability, congenital cataracts, and 
kidney problems. His previous research had revealed that, 
on the molecular level, Lowe syndrome causes prob-
lems with endocytosis, the process by which a vesicle 
empties its contents into a cell. Using super-resolution 
microscopy to monitor the distribution of the normal and 
mutant Lowe syndrome proteins on endocytic vesicles, 
De Camilli hopes to better understand the mechanisms of 
the disease, with implications for therapy.
Toomre is using TIRF microscopy to study diabetes 
by watching the way fat cells respond to insulin. When 
fat cells are stimulated with insulin, he has found, 
vesicles whose membranes contain sugar transport 
proteins rush to the cell membrane and fuse with it, 
adding the transporter proteins to the cell membrane 
and allowing the fat cells to take up more glucose. In 
diabetes, this process is somehow disrupted, and 
Toomre hopes to find out how. So far, he said, “Using 
this TIRF microscopy, we discovered that there were 
two different types of vesicles arriving at the surface, 
and until we could see it, we didn’t realize that.”
 … and in technology
On the cellular level, the Golgi apparatus is the new fron-
tier. In the lab, this new frontier is studded with giant 
microscopes enclosed in black boxes to keep out light 
and prevent temperature fluctuations. Bewersdorf walks 
me through his lab. His custom-made STED microscope 







































with eyepieces and a computer screen displaying an 
image. But nearby is a table with black sides reminiscent 
of a filled casket. Inside are black tubes with white labels, 
lined-up lenses of different tints, and blue and silver 
cables. The laser beam, he said, travels through the blue 
cables; the fluorescence travels to the detector through 
the silver ones. What’s good about these custom-built 
microscopes, Bewersdorf said, is that he can easily adjust 
them for different samples. 
“A lot of the things at the edge are not commercial. 
A lot of the microscopes that you’ll see in Joerg’s lab 
are custom-made,” said Toomre, “and they’re custom-
made because that’s the only way you can do it.”
Bewersdorf has achieved his goal of working with 
scientists in other fields, and the number of scientists 
who can thank him is likely to grow. “Super-resolution 
is something that just about everyone is trying to 
jump into,” said Michael W. Davidson, Ph.D., a Florida 
State University scientist who is collaborating with 
Bewersdorf and Toomre by providing fluorescent pro-
teins from his large collection. “It’s had a huge impact, 
but I think the impact is just starting. I think almost 
everybody’s going to be doing it within 10 years.”
Bewersdorf and Toomre are working with micro-
scope companies to commercialize the instruments that 
they have custom-built in their labs. For now, though, 
this is what Toomre calls “the edge,” the frontier of sci-
ence. I asked Bewersdorf if he thought the resolution of 
light microscopy would continue to improve. “No,” he 
said. The goals are no longer about resolution. Now the 
challenges are finding compatible fluorescent labels 
in order to watch multiple structures simultaneously 
and developing cameras that can capture the images 
faster and faster to create videos of cellular structures in 
motion. Perhaps the most important challenge is to apply 
this technological tool kit to questions of neuroscience, 
metabolism, and cancers whose answers may be cen-
tral to human health. Bewersdorf shows me a pointillist 
microscope, also custom-built in his lab. That microscope, 
armed with a digital camera, can take photos so fast that 
they can be used to create high-resolution movies of 
fluorescently labeled cells, as Bewersdorf and colleagues 
reported in a Nature Methods paper published online in 
May. I think back to Toomre’s analogy about trying to 
learn the rules of football from a snapshot. At last, a high-
resolution movie of cells at play. Now scientists can really 
learn the rules of the game. /yale medicine
Ashley Taylor is a freelance writer based in New York City.
Dyes and stains
In 1873, the Italian physician and scientist Camillo 
Golgi stained neurons using a silver compound that 
turned the cells black. The Spanish neuroanatomist 
Santiago Ramón y Cajal put Golgi’s method to fruitful 
use, making observations that led to the 
neuron doctrine, the now-accepted idea 
that the nervous system is composed 
of discrete cells. In 1886, Paul Mayer 
invented the hematoxylin and eosin 
staining procedure. Hematoxylin stains 
cell nuclei blue; eosin is nonspecifically 
attracted to proteins and gives the rest 
of the cell a contrasting reddish hue. 
The most important dyes used in light 
microscopy today, however, are fluorescent.
Fluorescence microscope
Though the fluorescence microscope was invented 
around 1910, fluorescence microscopy did not really 
take off until the end of the century, spurred by the 
development of fluorescent labels for specific bio-
logical structures. 
The most famous 
of these fluores-
cent tags is called 
green fluorescent 
protein, or GFP, 
a protein derived 
from jellyfish that 
emits green light 
when stimulated 
by blue light. [For more on the use of marine life 
as a source of fluorescent tags, see “In coral reefs, 
a treasure trove of tools” on next page.] In the 
1990s, scientists isolated the gene encoding GFP, 
which allowed them to engineer cells genetically 
so that GFP could be fused to a protein of interest 
for visualization with the fluorescence microscope. 
Microscopy’s palette expanded as scientists devel-
oped variations of GFP that fluoresce in different 
colors; and by labeling different structures with dif-
ferent fluorescent molecules that can be visualized 
at the same time, scientists can determine whether 
those structures are colocalized and potentially 
interacting. Fluorescent labels are not limited to 
proteins: they can also label DNA, lipid molecules, 
and carbohydrates. And efforts to break the diffrac-











































  In coral reefs, a  
treasure trove of tools
Few things are as mysteri-
ous and captivating as the 
ever-changing mosaic of colors 
emanating from the sea life 
in and around coral reefs. This 
shifting kaleidoscope of colors 
comes in part from tiny fluores-
cent proteins produced by coral 
and other marine species—part 
of a creative adaptation that 
helps them hide from predators, 
attract friends, and survive in 
the ocean’s battlegrounds. Now 
scientists are harnessing this 
evolutionary feat to develop 
novel, noninvasive ways to 
detect and monitor neurological 
and other diseases and, possibly, 
to tailor treatments.
Vincent A. Pieribone, 
Ph.D., professor of cellular and 
molecular physiology and of 
neurobiology, and other scien-
tists are using these proteins to 
expose the electrical activ-
ity of neurons and other cells, 
thereby making invisible cellular 
processes visible in ways that 
are not possible with conven-
tional imaging techniques.
For more than a decade, 
Pieribone and his team have 
been on a quest to find and clone 
new fluorescent proteins from 
such far-flung places as Austra-
lia’s Great Barrier Reef and the 
Solomon Islands. In the lab, they 
insert these proteins into ani-
mals to track and monitor brain 
activity and then decode how 
and when neural cells fire. When 
inserted into neural tissue, these 
fluorescent proteins produce 
a glow that is visible through 
the skull and skin, converting 
the surface of the brain into 
something akin to a television 
screen and revealing pictures of 
the processes within.
Every time the tissue 
produces an electrical signal, 
the intensity of light changes. 
These fluorescent proteins 
don’t just highlight the cells: 
Under certain conditions they 
can be stimulated to change 
the output of light intensity so 
that scientists can see biologic 
processes unfolding in real time. 
Using computers, researchers 
can record and observe this 
complex display of light over 
time to interpret the behavior of 
the neural tissue. Clinicians may 
one day be able to use these 
proteins to monitor and predict 
epileptic seizures.
“It’s allowing us to get 
a glimpse into the complex 
workings of the brain,” said 
Pieribone. “With these proteins, 
we can generate really powerful 
probes that we can then put into 
any cell and they will report the 
voltage of the cell as a change in 
fluorescence—it’s a real break-
through to optically look at cells 
firing at high speeds.”
The use of fluorescence 
in imaging has inherent benefits, 
too. It avoids the use of invasive 
electrodes, radiation exposure, 
or contrast agents. “We cur-
rently stick wire electrodes into 
the brain to touch the cells, and 
when they give off electrical 
bursts we can try to figure out 
what the brain is doing and say-
ing, but it’s invasive and causes 
permanent damage to the very 
organ you are trying to study,” 
Pieribone explained.
His work was initially 
inspired by the discovery in the 
early 1960s of a green fluores-
cent protein (GFP) in a species 
of jellyfish known as Aequorea 
victoria, which is indigenous 
to the Pacific Northwest. This 
discovery resulted in a Nobel 
Prize in chemistry in 2008 and 
has revolutionized biomedical 
research, he said.
Despite the discovery’s 
promise, Yale is one of the few 
academic centers in the world 
to engage in this type of field 
research. Pieribone has made 
a dozen trips to search some 
of the most diverse aquatic 
ecosystems for new fluores-
cent proteins. In all, Pieribone 
has identified over 100 species 
of fluorescent coral and other 
ocean life, most recently from 
eels and fish. “We have found 
fluorescent properties in a huge 
range of animals—far more than 
was thought possible,” said 
Pieribone. This discovery means 
greater opportunity and poten-
tial applications for medicine.
The irony, he says, is that 
the very coral reefs that produce 
these proteins—molecules hu-
mans could never invent on their 
own—are disappearing. The reefs 
are sensitive to warmer ocean 
temperatures and pollution, 
which cause them great stress 
and leave them vulnerable to 
disease. “We have these libraries 
of cool proteins vanishing from 
the earth as quickly as we can 
get them, clone them, and study 
them,” he said.
What does the future of 
fluorescent protein technology 
hold?
While scientists are 
now using light to interact with 
nervous tissue both to observe 
and to control what the brain 
is doing, researchers believe 
that these proteins might lead 
to better treatments down the 
line, perhaps even linking mind 
to machine. For someone with 
a spinal cord injury, for example, 
where the brain no longer com-
municates with the body, the 
hope is that a computer could 
convert brain activity— such 
thoughts as, “I want to pick up 
that glass”—into action.




















can brain scans  
reveal  
how we think?
Scientists debate whether such higher-order  
processes as consciousness and  
morality have their own real estate in the brain.
By Jenny Blair Illustration by Francis Blake
In the not-too-distant future, a clinician in that position 
might turn to brain imaging for answers. Using func-
tional magnetic resonance imaging (fMRI), a method 
that maps neural activity to specific locations in the 
brain, Yale scientist Dongju Seo, Ph.D., and Rajita Sinha, 
Ph.D. ’92, Foundations Fund Professor of Psychiatry, 
professor of neurobiology, and in the Child Study Center, 
examined 45 alcohol-dependent patients and compared 
the scans of those who later relapsed to the scans of 
those who did not. Surprisingly, when the relapse group 
tried to mentally relax, the prefrontal cortex failed to 
settle, and during stressful thoughts, it failed to activate, 
according to their study in JAMA Psychiatry in May. If 
your brain activity looks like that, you’re less likely to 
stay sober—or so, apparently, says the scan.
fMRI is the closest we can come to watching the 
brain at work. Its vividly colored images seem to offer 
snapshots of thought and emotion themselves. The 
central tool of many brain researchers at Yale and 
around the world, fMRI holds the promise of illumi-
nating the brain-mind connection.
S OM E PE OPL E W I T H A L C OHOL I S M  can change their behavior and remain 
abstinent, while others fight the battle over and over again. And while 
treatment for alcohol abuse is often effective, many patients wind up back-
sliding. If clinicians knew which ones are most likely to do so, they could 
intervene to help them stay sober. 
“It provides information that can’t be obtained with 
any other approach right now,” said Hal Blumenfeld, 
M.D., Ph.D., FW ’98, professor of neurology. The 
method is noninvasive and shows the whole brain at 
once, with better resolution in time and space than 
older methods can offer.
Certainly, fMRI’s ability to peek into our heads 
hasn’t been lost on lawyers, advertisers, and entrepre-
neurs. Brain scan findings have been used in court to 
defend sociopaths, while “neuromarketers” have used 
fMRI to measure audience reactions to a Harry Potter 
movie trailer. A company called No Lie MRI claims to 
have developed a reliable lie detector test—or “truth 
verification technology”—based on fMRI.
Yet as the technology comes of age, some observers 
of the field are calling for caution, and earlier this year 
two Yale authors published books arguing that fMRI is 
all-too-often misused. In Brainwashed: The Seductive 
Appeal of Mindless Neuroscience, co-author Sally Satel, 
M.D., HS ’88, a lecturer in the Department of Psychiatry, 
examines the implications that our hasty embrace of 
fMRI may have for the concepts of free will and human 
agency. Amid the popular enthusiasm for brain images, 
she argues, misunderstandings abound and dubious con-
clusions are often drawn. For example, when predicting 
an alcoholic patient’s behavior with fMRI findings, she 
said, we risk falsely concluding that relapse is inevitable.
In his recent book, Brain Imaging: What It Can 
(and Cannot) Tell Us About Consciousness, Robert G. 
Shulman, Ph.D., professor emeritus of molecular bio-
physics and biochemistry, questions whether fMRI 
should be used to study such higher-order cognitive 
processes as working memory, attention, and conscious-
ness. A biophysicist who pioneered the technique in the 
early 1990s, Shulman believes that the design and inter-
pretation of many studies that use it have been faulty. The 
brain, he argues, is best studied just like any other organ—
via a physiologic approach that can identify neural 
  Hal Blumenfeld // 
 “What [fMRI] does is provide  
a wonderful initial draft or road  
 map of structures that could be  
  important and that should  
 be investigated through  
   other techniques. ’’
yalemedicine.yale.edu24
The debate over localization long predates the introduction of fMRI. In the early 19th 
century, Franz Joseph Gall, the founder of the now-discredited discipline known as 
phrenology, proposed that the brain comprised distinct functional units whose usage 
was reflected by bumps in the skull. But when experimental physiologists of that era 
tried to confirm this notion by studying brain damage in birds, they failed to find 
specific functional losses.
Later, studies of human strokes, the discovery of neurons, and the beginnings 
of a distinction between localized symptoms and localized functions continued to fuel 
arguments about whether brain functions are discrete and easily mapped.
Some researchers think that the truth lies between the two extremes: simpler func-
tions are localized in modules, or specific areas, while more complex ones are distributed. 
“You have some modularity,” said Yale’s Douglas Rothman, Ph.D. ’87, “but the modularity 
itself is supported in networks, not in discrete regions completely responsible for complex func-
tion.” (Or, as Sally Satel, M.D., and her co-author, Scott O. Lilienfeld, Ph.D., put it, “most neural real 
estate is zoned for mixed-use development.”) 
“Mixed-use development” 
in the brain
processes that are necessary for a person’s behavior.
But many neuroscientists believe that fMRI can 
indeed get at higher-order functions—especially when 
combined with other measurement methods—and that 
research methodologies are improving, reducing the risk 
of unwarranted conclusions. They say that Shulman’s 
call to limit themselves to neurophysiology and behavior 
would do science and patients a disservice.
present at the creation
Shulman was among the first physicists to study bio-
logical systems with nuclear magnetic resonance, and 
by the late 1970s, working at Bell Labs, he was using 
it to study how glucose is metabolized in yeast and 
muscle. That decade also saw the first magnetic reso-
nance images and the first whole-body MRI scanner. 
Improvements in MR technology set the scene for the 
development of functional MR imaging at Yale and the 
University of Minnesota in 1992 (see sidebar: “BOLD 
beginnings,” page 26).
MR imaging had been a major advance in revealing 
anatomical structures. Functional MR went a big step 
further by mapping brain activity to specific locations 
and superimposing that data over the MR image.  
It exploits the propensity of hemoglobin to behave  
differently in a magnetic field—depending on whether  
or not it is oxygenated—a principle called blood- 
oxygenation-level-dependent (BOLD) imaging. Because 
active neurons consume oxygen, the brain compensates 
by sending oxygen-rich blood their way; fMRI can map 
areas of neuronal function by tracking the flow of oxy-
genated hemoglobin.
After the initial studies in 1992, scientists rushed 
to adopt fMRI, finding it a faster, more accurate, and 
more accessible way to image brain activity than such 
older technologies as positron emission tomography, 
or PET. Early experiments yielded detailed, reproduc-
ible maps of brain areas corresponding to sensory and 
visual stimulation. The technique has been central to 
the advent of cognitive neuroscience, a developing field 
that studies the neural basis of higher brain functions. 
Cognitive neuroscience studies have implicated the 
amygdala, for example, in evaluating threats and medi-











































of the brain normally associated with recognizing 
objects. The finding caused a sensation in the autism 
community—it seemed to explain why autistic chil-
dren tend to show little interest in faces. Their 1997 
work followed studies by a group at Yale led by Gregory 
McCarthy, Ph.D., and by another group at Harvard 
and Massachusetts General Hospital led by Nancy 
Kanwisher, Ph.D. She and colleagues including Marvin 
M. Chun, Ph.D., now a professor of psychology at Yale, 
showed that this brain region—the fusiform face area—
is selectively activated by faces, confirming years of 
suggestive but ambiguous data from other methods. It 
is today the most-cited fMRI brain research paper in 
the scientific literature.
where mor alit y and memory reside?
Shulman believes that many fMRI studies are too 
ambitious. Mapping brain areas specialized for sen-
sory or motor systems is one thing. Mapping the life of 
the mind is quite another. Memory and attention are 
subjective processes that cannot be experienced by an 
observer, and they may not be as discrete as we think 
they are. We talk about remembering to pick up the 
kids or remembering a phone number, but those two 
acts may not be as fundamentally similar as our single 
term for them would imply. “When you start looking 
for localization of concepts like honor, values, moral-
ity, memory, consciousness, you aren’t going to find 
them,” Shulman said, “because we have never learned 
exactly what they are.” Shulman points to a UCLA 
study purporting to show that Republicans have higher 
amygdala activation and are more likely to vote based 
on fear and other emotions. Such experiments, he said, 
constitute “phrenological fMRI,” a term critics have 
used since the early 2000s to dismiss such research.
To grapple with such objections, it’s important to 
understand a few things. For one, the brightly colored 
images that appear in journals and news reports usu-
ally don’t represent one brain at one time; rather, they 
represent highly processed, composite results obtained 
by processing several individuals’ brain data through 
statistical algorithms (see sidebar: “How functional 
MRI works,” page 29). Moreover, these algorithms rely 
on assumptions not everybody agrees on.
Second, BOLD imaging has important limitations. 
Though increased oxygen-rich blood and its stronger 
BOLD signal usually flag increased neuronal activ-
ity, there’s a time lag, since neurons fire thousands of 
times faster than blood flows. Moreover, sometimes the 
BOLD signal is positively misleading. Yale’s Blumenfeld 
The BOLD effect—tracking neuronal activity 
through blood flow—was first demonstrated in 
small animals in 1990 by one of Robert Shulman’s 
former Bell Labs postdocs, Seiji Ogawa, Ph.D. Then, 
Ogawa and another former Shulman postdoc, 
Kamil Ugurbil, Ph.D., used the method to produce 
the first functional magnetic resonance images 
(fMRI) of humans at the University of Minnesota.
Shulman, who was using magnetic resonance 
spectroscopy to study metabolic changes in the human 
brain, saw an opportunity to get similar information at 
much higher spatial and temporal resolution. His Yale post-
doc Andrew Blamire, Ph.D., had learned a technique called 
echo planar imaging that sped up the process of captur-
ing MR images and was considered critical for exploiting 
the potential of the BOLD effect for mapping brain func-
tion. Shuman directed Blamire, along with fellow postdoc 
Douglas Rothman, Ph.D. ’87, and Terry Nixon, now director 
of facilities at Yale’s Magnetic Resonance Resource Center, 
to soup up the lab’s outdated MRI system to incorporate the 
speed of echo planar imaging. 
When Ogawa and Ugurbil heard that the Yale system had 
rapid imaging capability, they began a collaboration with 
Shulman. This work, which also included Gregory McCarthy, 
Ph.D., now a professor of psychology at Yale, led in 1992 to 
one of the earliest fMRI studies, the first to show the brain 
responding to individual events, in this case a single visual 
stimulus. Shulman’s team subsequently collaborated with 
McCarthy to perform the first fMRI measurements of a person 
performing a cognitive task.
BOLD beginnings
appear to be critically important for relational memory, 
which allows us to associate names with faces. Parts of 
the prefrontal cortex seem to power down in schizo-
phrenia, and so on. Previous methods had produced a 
great deal of information about the functions of these 
and other brain areas, but fMRI allowed scientists to ask 
more sophisticated questions and clarify what they pre-
viously had only suspected was true.
In 2000, for example, investigators at Yale’s Child 
Study Center found evidence, through fMRI, that sub-
jects with autism don’t process faces in the brain’s 




































and his colleagues were the first to show that, in some 
seizures, neurons fire in such a frenzy that they need 
more oxygen than the brain can deliver and the BOLD 
signal goes down instead of up. They also found that 
blood flow sometimes declines in response to neuronal 
activity. These findings strike at the heart of all BOLD 
assumptions. “Taking BOLD alone is always going to 
be potentially risky,” said Blumenfeld. “Everyone is 
hoping for [better] techniques. ... I’ve been hoping for it 
my whole career.”
Third, and perhaps most importantly, experimental 
premises are crucial. Cognitive neuroscience assumes 
that mental processes like working memory, attention, 
problem-solving, and decision-making are real, objec-
tive, measurable, observable phenomena. Especially in 
the early years of the field, cognitive neuroscientists 
believed that these brain functions reside in discrete 
modules, a school of thought called localizationism. 
Many researchers have come to believe that these func-
tions are organized in networks. Others posit that the 
whole brain is involved in all functions—the aggregate 
field view (see sidebar: “ ‘Mixed-use development’ in 
the brain,” page 25).
These things matter because 
they affect how a researcher 
plans and interprets experi-
ments. A localizationist who 
expects working memory to 
reside in one particular spot in 
the prefrontal cortex will nat-
urally process his data to look 
for that area lighting up. But 
there are other ways to analyze 
the same data set that can lead 
to different conclusions about 
which areas of the brain are 
active during a cognitive task. 
Chun said he believes 
that Shulman “has appropri-
ately urged caution over the 
years, but his concerns do not 
acknowledge all the recent 
advances in analysis meth- 
ods that enable more precise  
interpretation of BOLD signal 
activity for understanding  
perception and cognition.”  
As an example, he points to  
the work of Jack L. Gallant, 
Ph.D. ’86, at UC Berkeley. 
ABOVE This graphic highlights areas of the brain 
where Yale researchers found significant dif-
ferences in responses to stress and relaxation-
inducing stimuli between alcoholic patients and 
healthy controls.
BELOW Robert Shulman (left) with Todd Constable 
and Douglas Rothman, co-directors of the Magnetic 








































































signal remains may show the area of brain involved 
in that task, though this deduction contains many 
pitfalls—correlation does not imply causation, and 
seemingly simple cognitive tasks may comprise 
multiple simpler processes. Yet the signal from a 
single task can be extremely faint amid the brain’s 
busy baseline activity. Without subtraction the 
two scans might look nearly identical. 
Combining data from multiple research subjects 
is crucial, but it, too, can be dicey. The statistics 
may not take into account the anomalies that often 
dog complex experiments, such as missing data 
or a subject with a truly unusual brain signal. And 
individual subjects’ anatomical differences are often 
blurred during normalization, which means losing 
potentially important information.
Because of an fMR image’s colors, we say that 
the brain “lights up” in response to some mental 
task. But in reality nothing “lights up”; these colors 
are simply a code for the relative strength of the 
signal within each voxel. To judge whether that sig-
nal is random or real, researchers must also choose 
a threshold, or p-value, that represents the likeli-
hood of a particular result being due to chance. A 
common p-value in statistics is 0.05, or 5 percent, 
meaning that an acceptable result is no more than 
5 percent likely to be due to chance alone. But some 
fMRI researchers call for p-values as strict as .005, 
reasoning that they’ll find fewer false positives that 
way. False positives are a real danger, as one group 
famously demonstrated by “finding” areas of brain 
activation during an fMRI analysis of a dead salmon. 
Unfortunately, stricter p-values might eliminate 
important data from consideration.
Statisticians are working on ways to refine all 
these analyses in hopes of ensuring that what “lights 
up” during a cognitive task reflects real, significant, 
and specific brain activity. But in the meantime, it’s 
best to bear in mind that an fMR image is more like a 
graph than a photo. Like any image born of statistics, 
it can both enlighten and mislead.
Don’t let that detailed image throw you. Unlike, 
say, X-rays, a functional magnetic resonance 
image (fMRI) isn’t a snapshot. It’s a statistical map, 
the colorful end product of massive calculations.
During an fMRI experiment, researchers typi-
cally scan the brain at rest and then during a series 
of such tasks as recalling a string of numbers. This 
technique yields hundreds of images, each con-
taining information about changes in metabolism 
and blood flow. These changes are associated with 
neuronal activity, measured in voxels by the tens 
of thousands. (A voxel is a cube-shaped data unit 
analogous to the 2-D pixel.) Long after the person 
being scanned has gone home, the researchers 
must contend with gigantic amounts of raw data. 
First, in a step called preprocessing, researchers 
correct the data. There is slice-timing correction, 
since not all “slices” of the brain are imaged simul-
taneously. There is motion correction, since subjects 
tend to move during scans. Low-resolution fMRI data 
are superimposed onto a standard “template brain” 
image obtained by regular MRI (coregistration), but 
these have to be corrected because not everyone’s 
brain neatly matches the template (normalization). 
Then comes data analysis—researchers try 
to isolate those areas and networks that sent 
a stronger signal during a specific mental task. 
Subtraction is a common approach, in which the 
signal obtained at rest is “subtracted” from the 
one obtained during the task. To further localize 
the mental process being studied, images obtained 
during the study task may be subtracted from 
images captured during a control task. Whatever 
How functional MRI works
The fMR images in this series show the brain’s 
response to changing oxygen levels by overlaying 
results from a group of participants in a study of  
genetic influences on reading ability. The results 
from all 179 subjects were combined into a whole-
brain statistical map of areas showing significant 
BOLD signal changes.
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Gallant’s group has produced highly complex, interac-
tive brain maps, derived from enormous datasets that 
attempt to correlate the neocortical activity of study 
subjects with hundreds, even thousands of objects and 
actions observed by the subjects. The resulting images 
and word maps, when viewed dynamically on a com-
puter, are far more nuanced than the 2-D brain slices 
that have become familiar since the first fMRI studies 
in the early 1990s.
a change of mind
Shulman recalled that shortly after the development of 
functional imaging, the idea of modules for memory, 
consciousness, and other cognitive concepts raised 
hopes that finding where they reside would explain 
them at last. “Well,” he said, “that did not work.” 
Initially excited by the promise of fMRI to explore cog-
nition, by the mid-1990s he had conducted an experi-
ment that changed his mind. He showed that a certain 
region of the frontal cortex lit up during a task of 
working memory. After publishing his results, he real-
ized that he hadn’t demonstrated that this response 
was unique. Repeating the experiment with an atten-
tion task, he found that the very same area lit up—a 
contradiction of the assumption that different mental 
activities occupy distinct, nonoverlapping modules in 
the brain. At the same time, metabolic studies showed 
that even at rest the neuronal activity of the brain is 
very high. An absence of change in activity during 
a task did not mean a brain region was not involved 
in supporting it; instead its activity could just be the 
same in the task and control states.
Shulman had committed the reverse inference 
error—working backwards to link activity in a brain 
region to a specific cognitive function. This error is 
one that he and cognitive neuroscientists agree has led 
many fMRI researchers to overstate their results. (In 
contrast, Chun’s 1997 paper on the fusiform face area 
asserted that it is selectively activated by faces, a con-
clusion drawn after comparison with various control 
actions and objects is organized spatially across the 
cortex—but without the 1-to-1 specificity implied 
by earlier methods of visualization using fMRI.
Jack Gallant’s lab at UC Berkeley has extended the 
boundaries of fMRI visualization by creating an 











































stimuli.) Shulman came to believe that the very philo-
sophical underpinnings of such experiments are shaky, 
since they assume a modularity that isn’t neatly borne 
out by the findings. Context is all-important: how 
working-memory tasks look under fMRI varies widely, 
depending on the nature of the task.
A more effective use of fMRI, argues Shulman, 
would be to characterize the brain’s activity during 
observable behaviors in brain imaging studies. “For 
example, the total brain activity necessary for a per-
son to perform the act of memory can be observed,” 
he said. “The location of the psychological concept of 
memory cannot.”
Critics’ concerns aren’t limited to experimental 
method; like Satel, some argue that results are being 
exaggerated. In an opinion piece in The New York Times 
the authors of the UCLA politics-related study claimed 
that fMRI results revealed how 20 voters felt about 
Hillary Clinton and Mitt Romney. Exasperated neuro-
scientists at a dozen universities responded in a letter to 
the Times—it’s not possible, they said, to determine a 
person’s mental state by looking at a brain scan.
Contrary to hopes, Satel argues, the technology 
cannot sway voters, sell products, sniff out lies, or 
reveal the causes of crime and mental illness. “To 
regard research results as settled wisdom,” she writes, 
“is folly.”
Satel views neuroscience and its tools as nothing 
short of remarkable. But she thinks that we are too 
quick to believe that this young science has at last 
illuminated the mind-brain relationship. Our rush to 
explain complex behaviors via brain activity alone fails 
to take psychological or social factors into account—
and can lead us astray. She is skeptical, for example, of 
the way that fMRI findings have been used to argue 
that addiction is a purely a brain disease. Moreover, 
she writes, “the fact that addiction is associated with 
neurobiological changes is not, in itself, proof that 
the addict is unable to choose.” Recovery programs 
that make use of incentives and consequences work 
for addicts, she pointed out, but would never help a 
Parkinson patient.
the br ain’s  integr ated net works
Like psychologist Chun, Marc N. Potenza, Ph.D. ’93, 
M.D. ’94, believes that our understanding of brain 
organization is outgrowing its initial simplicity. 
Potenza is a professor of psychiatry, neurobiology, and 
child study who uses fMRI to study behavioral addic-
tions like compulsive gambling.
Conventional wisdom, he said, held until recently 
that the amygdala processed fear, the ventral stria-
tum provided drug-induced rewards, and so on. But 
these brain regions have been implicated in other pro-
cesses as well, pushing cognitive neuroscience toward 
a network-based model. “The way in which these 
regions work together in networks or functionally 
integrated activations that some MRI data can iden-
tify, that’s really important,” Potenza said. The Human 
Connectome Project, in which research universities 
share fMRI data on brain networks, is a first attempt at 
mapping such connections.
Adoption of a network model isn’t the only shift in 
thinking. Researchers are using fMRI results to break 
traditional concepts like working memory into such 
smaller and more isolable components as encoding, 
shifts of attention, and retrieval. They are also study-
ing the default mode network, brain activity when a 
person is awake but not doing anything in particular, 
using both cognitive and physiological approaches.
There is also brain plasticity to consider. Existing 
functional connections in the brain can be readily 
altered through learning and experience—and we can 
see those changes on fMRI.
Potenza rejects the idea that only behaviors observ-
able by others constitute the proper subject of fmri 
study. “There are some conditions like major depres-
sion where subjective accounts are very important to 
understand,” he said. “If we were to omit looking at 
subjective responses, motivational states, emotional 
states, we would be limiting ourselves with respect to 
our understanding of the human condition in multiple 
clinically relevant states.”
Perhaps some of today’s popular fMRI applications 
will recede into history, taking their place alongside 
early 20th-century electrical healing gadgets and 
shoe store X-ray machines. Satel believes this burst 
of exuberance, if sometimes troubling, is normal in 
these early days of contemporary brain science. “You 
start out a little more crude, and then you perfect 
and perfect and perfect,” she said. “Wherever we are 
in 20 years, I doubt we’d be there had we not gone 
through this phase first.” /yale medicine
Jenny Blair, M.D. ’04, a freelance writer based in Austin, Texas, is a 
frequent contributor to Yale Medicine.
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  How neurofeedback  
 helps patients tamp   
   down their fears
Tiny parts of the brain, School of 
Medicine researchers are discov-
ering, can have a huge impact 
on our lives. Michelle Hampson, 
Ph.D., and Judson A. Brewer, 
M.D., Ph.D., are leading teams 
that use real-time fMRI and 
what’s known as neurofeedback 
to try to teach people how to 
control brain activity and combat 
such problems as anxiety, ad-
diction, Tourette syndrome, and 
post-traumatic stress disorder 
(PTSD), as well as more mundane 
self-imposed roadblocks to 
success.
Hampson, an assistant 
professor of diagnostic radiology, 
in collaboration with Christopher 
Pittenger, Ph.D., M.D., associ-
ate professor of psychiatry, 
has been working to develop 
treatments for people afflicted 
with obsessive-compulsive 
disorder. One common symptom 
of this disorder is contamination 
anxiety (CA). Sufferers can be 
crippled by fears of infection by 
anything from microbes to moral 
turpitude. Previous research 
suggests that the problem arises 
from hyperactivity in the orbi-
tofrontal cortex (OFC). Existing 
therapies are not always reliable, 
and known drugs are not always 
  By Bruce Fellman
effective, so Hampson tried using 
real-time images of the over-
wrought brain and neurofeed-
back methods to enable subjects 
to calm things down.
The team worked with 
20 healthy adults, all of whom 
had CA. While in an fMRI scanner, 
subjects were shown a series 
of such anxiety-provoking 
photos as moldy fruit and skin 
infections, along with such 
neutral pictures as a backpack 
and a tranquil countryside. 
The subject’s task was to try 
to control hyperactivity in 
the OFC. Half the group saw a 
genuine real-time line graph 
that provided neurofeedback 
by depicting OFC activity; the 
control group watched a sham 
graph. Both groups attempted 
to manipulate the graph—and 
control their OFC activity—by 
using anxiety-lowering strate-
gies. There was no one-size-fits-
all approach—some participants 
tried to tamp down their feelings 
in response to a picture, while 
others invoked religious beliefs, 
said Hampson, whose study was 
published online on April 30 in 
Translational Psychiatry. 
“Not only were the subjects 
in the treatment group signifi-
cantly better at controlling their 
CA, but the changes persisted for 
at least several days.”
Hampson is also working  
with real-time fMRI and neuro-
feedback as a way to enable 
patients to control the tics asso-
ciated with Tourette syndrome, 
and she and other researchers 
are investigating their use as a 
treatment for PTSD. “We look for 
mental disorders with a distinc-
tive brain signature—either 
hyper- or hypoactivity—that can 
be spatially localized,” Hampson 
explains. “If we know what’s 
unhealthy in terms of brain 
activity, we can try to come up 
with specific neurofeedback 
strategies that move the pattern 
in a healthy direction.”
Of course, one group of 
people—experienced medita-
tors—has been using neurofeed-
back techniques for thousands 
of years. Brewer, assistant 
professor of psychiatry and a 
veteran meditator, has studied 
practitioners of this ancient dis-
cipline. Using real-time fMRI and 
neurofeedback, Brewer and his 
colleagues have figured out how 
meditation can control an oddly 
fundamental brain behavior 
called mind-wandering. “This 
must have been adaptive at one 
point in our evolution, but we no 
longer know how to turn it off,” 
he explains.
Run-of-the-mill daydream-
ing can be counterproductive 
enough, but the former soldiers 
he works with at the Veterans 
Administration Healthcare 
System in West Haven may be 
utterly disabled by their inability 
to stop recurrent war visions. To 
help vets and others, Brewer and 
his team are especially interested 
in the posterior cingulate cortex 
(PCC), one of the major hubs of 
a mind-wandering circuit called 
the default mode network. “The 
PCC is activated when you’re 
anxious, when you’re thinking 
about yourself, when you’re 
planning for the future, and 
when you’re experiencing crav-
ings—any time you get caught 
up in something,” said Brewer. 
“It’s the big mover and shaker.”
But when it moves and 
shakes too much, one untoward 
result, he continues, is that “we 
tend to get in our own way.”
In an investigation using 
real-time fMRI and neurofeed-
back soon to be published in 
NeuroImage, Brewer and his 
team compared the ability of 
meditators and non-meditators 
alike to dampen the PCC. Not 
surprisingly, the meditators were 
more than up to the challenge. 
“Meditators, through years of 
practice, have learned how to get 
caught up in the moment and, 
maybe more important, how to 
let go,” said Brewer, who directs 
the Yale Therapeutic Neurosci-
ence Clinic at the VA.
“A wandering mind is an 
unhappy mind,” Brewer explains. 




















When Dennis Spencer (left) began his career in  
neurosurgery in the early 1970s, he had two  
X-ray technologies at his disposal for brain  
imaging. Now, he says, imaging technology  
has “revolutionized every field.”
a new vision in the lab 
and in the clinic
Since the discovery of X-rays in the 19th century,  
new imaging technologies have helped physicians peer into the  
causes of disease and provide better clinical care.
By John Dillon Photos by Robert Lisak
Spencer then had two X-ray imaging tools at his dis-
posal. One was angiography, introduced in 1927 but  
still widely used, in which an injected dye illuminates  
a patient’s blood vessels on X-ray. The other was  
pneumoencephalography, a painful invasive procedure 
dating back to 1919 that involves draining fluid from 
the brain and injecting air into its ventricles to prepare 
for an X-ray. “It was a pretty crude field at the time,” 
says Spencer, chair and the Harvey and Kate Cushing 
Professor of Neurosurgery.
This antediluvian period ended by the mid- to late-
1970s with the advent of computer-assisted tomogra-
phy (CAT or CT) X-ray scans, which enabled Spencer to 
see blood, soft tissue, and some tumors noninvasively. 
Imaging capabilities accelerated in the 1980s with the 
development of magnetic resonance imaging (MRI or 
MR), which provides even sharper internal images with-
out exposing the patient to radiation; and then positron 
emission tomography (PET) imaging, which detects 
changes at the cellular level. These and other devices—
boosted by increasingly powerful computers and often 
used in combination—have radically improved the detec-
tion and treatment of disease.
Today Spencer can remove or stimulate parts of the 
brain responsible for intractable Parkinson or epilepsy 
and leave vital parts intact. “I can put an electrode within 
two millimeters of any part of the brain,” he says.
Yale clinicians and scientists are seizing on the imag-
ing boom to improve patient care. Advanced techniques 
have moved from the lab to the clinic and the operating 
room and have become key tools for quicker, more accu-
rate diagnoses and better outcomes. Surgeons can now 
see inside a patient’s body in three dimensions in real 
time while they operate. Imaging technology can identify 
the places to avoid during brain surgery, whether a can-
cerous prostate should be left alone, or whether a breast 
mass is normal or cancerous. Imaging modalities can 
not only make surgery more precise but may also help a 
patient sidestep an operation or biopsy altogether.
W H E N DE N N I S S PE NC E R, M.D.,  R E C A L L S H I S F I R S T DAYS  as a neurosurgeon in 
the early 1970s, he doesn’t wax nostalgic about the way he imaged a patient’s 
brain. “We weren’t that far from Harvey Cushing,” he says, referring to Yale’s 
renowned “father of neurosurgery” and X-ray pioneer, who died in 1939.
“When I started, I thought I was getting in on the tail 
end of the developments of MR,” says R. Todd Constable, 
Ph.D., professor of diagnostic radiology. “It turns out, 
23 years later, that it hasn’t matured yet.” Constable, a 
physicist, is often called on to find the best device (or 
devices) for other specialists, and his team uses those 
modalities to develop a clinical map of the inside of a 
patient’s body. Everyone thought CT scanning “was 
done” by 1990, he says, but the development of multi-
detector, multi-slice imaging extended its warranty. 
“There’s still a revolution in imaging for modalities we 
discovered years ago that we thought were mature,” 
Constable says.
from x-r ay to fmri
The first great step in medical imaging came in 1895, 
when Wilhelm Röntgen took an X-ray of his wife’s 
hand, famously displaying her bones and wedding ring. 
Cushing, then only 26 and a newly minted M.D., rec-
ognized the significance of the device and put X-rays to 
clinical use within months. But X-rays went only so far 
because they allowed medical professionals to see bones 
or teeth but little else.
Ultrasound, which creates images through sound 
waves and is familiar to any expectant parent, came 
into use in the 1950s. Constable says ultrasound didn’t—
and still doesn’t—deliver clear images, but it has the 
advantage of being safe, affordable, and nowadays, 
highly portable. The next huge advance came in the 
1970s, when the London-based Electric and Musical 
Industries developed the CT scan. The CT scan was 
the first to deliver X-ray images of the body in cross 
sections, and the images could be viewed either as 
individual slices of bread or an entire loaf. By the next 
decade, MRI, which uses magnetic fields and radio 
waves to capture images of internal organs, began pro-
viding even clearer shots of soft tissue.
Further breakthroughs in medical imaging came 
from unexpected sources—computer graphics and the 
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film industry. “We can all thank Hollywood and the 
gaming industry,” says Xenios Papademetris, Ph.D., an 
associate professor of diagnostic radiology, who pre-
pares surgeons for procedures by mapping a patient’s 
brain or other body part ahead of time. Graphics cards 
were “designed to let kids play games,” he says. “We’re 
using them to do other things.”
Constable works with Spencer and other research-
ers by preparing images for their research or surgical 
procedures and says that the technology has made Yale a 
leader in providing surgical treatments for patients with 
epilepsy who don’t respond to drugs. “Things are mov-
ing from the research lab—where we can image these 
different aspects of brain function or brain metabo-
lism or what have you—and into the sort of real-time 
intraoperative mapping,” Constable explains. When, 
for instance, epilepsy patients are being prepared for 
surgery, they’ll first get an fMRI. “When you speak in 
the magnet, or read, we can isolate your 
language cortex,” Constable says. During 
an operation, a surgeon can see where that 
spot is and knows not to “cut that cortex 
because [the patient’s] not going to be able 
to speak afterwards.”
Epilepsy is Spencer’s specialty, and the 
technology helps him track the origin of 
seizures. He’ll cut open a patient’s skull 
and—with the help of people like Constable 
and Papademetris—implant a grid over the 
brain, leaving it there for 10 days while he 
monitors brain activity. During that time 
the patient’s epilepsy drugs are withdrawn, 
and the monitor lets Spencer see which 
parts of the brain are initiating seizures. 
Information is collated with the patient’s 
CT scans to find the problem spot, which 
Spencer can locate on the axes of the grid 
as a player might do in a game of electronic 
Battleship. Electrical stimulation, again 
guided by imaging, identifies such critical 
function regions as language. He’ll go back 
into the patient’s brain and resect diseased 
areas, sparing function.
Two operating rooms at Smilow Cancer Hospital at 
Yale-New Haven have MRIs specially built for surgery, 
including the world’s first combination intraoperative 
MRI/endovascular suite. There, Spencer’s neurovas-
cular faculty uses the MRI and a biplane angiography 
device that produces 3-D images of the blood vessels in 
the brain. He says the improved images have drastically 
changed the treatment of brain aneurysms. Ten years ago, 
90 percent of arterial bulges were controlled by placing 
clips on them. Today, aneurysms are more often secured 
internally by coils inserted by a microcatheter—a safer, 
less-invasive method—and the use of clips has fallen to 
between 30 and 40 percent.
preventing false posit ives
While Spencer often uses imaging as a tool during an 
operation, Liane Philpotts, M.D., chief of breast imag-
ing at Yale, will happily employ it to prevent a false 
positive. In addition to ultrasound and MR, she says that 
Yale has the best mammography technology yet: digital 
breast tomosynthesis.
Tomosynthesis, approved by the Food and Drug 
Administration in 2011 after trials at Yale and four other 
medical centers, is the first technology to deliver three-
dimensional images in mammography. When used in 
Liane Philpotts uses digital breast tomosynthesis 
to cut down on false positives and make more 
accurate diagnoses for breast cancer. Suspicious-
looking images can bring back about one patient  
in 10 for more tests—usually false alarms. But,  
Philpotts says, “anybody who gets called back 
thinks the worst.” Tomosynthesis, which was 
approved by the FDA in 2011 after trials at Yale and 
other medical centers, is the first technology to de-
liver three-dimensional images in mammography.
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progresses, she spots a telltale spidery lesion that indi-
cates cancer.
In 2009, the U.S. Preventive Services Task Force 
(USPSTF), a group of outside advisors to the Department 
of Health and Human Services, recommended that 
women over 50 have mammograms every two years 
instead of yearly. Citing the cost of false positives and 
the radiation younger women are exposed to, the panel 
suggested that women in their 40s not get screened 
unless they are in a high-risk group. Those recommen-
dations were “controversial,” Philpotts says, conflicting 
with those of groups like the American Cancer Society, 
which continued to back yearly mammograms for 
women between 40 and 49.
Philpotts thinks that 3-D imaging can help bridge the 
gap between the conflicting recommendations. A team at 
Smilow Cancer Hospital reviewed the mammograms of 
14,684 patients and found that the cancer detection rate 
was 5.7 per 1,000 patients in those who underwent both 
2-D and 3-D screening compared to 5.2 per 1,000 among 
those who had only a standard mammogram. Subsequent 
ongoing data collection has shown an even greater differ-
ence in cancer detection. Moreover, 54 percent of those 
whose cancer was detected with the combined imaging 
had dense breasts; of those whose cancer was identified 
by 3-D imaging only, 21 percent had dense breasts. In 
2009, Connecticut became the first state in the nation to 
mandate that women be notified if a mammogram shows 
that they have dense breast tissue and that their insur-
ance pay for additional screening.
With 3-D imaging, Philpotts said, the 
risk of false positives is reduced. “We’re 
saving on the costs of unnecessary diag-
nostic workups and possibly biopsies.”
At the start of her career 20 years ago, 
“when you had a finding, you had to go to 
the OR,” Philpotts says, but today “very 
few patients need to be taken to surgery.” 
The 3-D machine can reduce the number 
of callbacks, but those who must return 
also benefit from better imaging, which 
guides doctors through a real-time core 
conjunction with traditional 2-D images, tomosynthesis 
cuts down false positives by 30 to 40 percent, Philpotts 
says. It has also increased the rate of cancer detection by 
up to 20 percent. “Tomosynthesis is a game-changer,” 
she says. “It’s a win-win.”
Traditional mammograms can’t always distinguish 
cancerous cells from harmless ones. This lack of clarity 
is especially problematic in patients—usually younger 
women—with dense breasts, which have more glandular 
than fatty tissue. “Fat we can see through,” Philpotts 
explains. Glandular tissue, however, appears as white on 
an image, as do cancer cells. “This is one of the limita-
tions of mammography.”
Philpotts shows the difference in the images of a 
patient who underwent both a standard mammogram 
and tomosynthesis. The procedures are roughly the same 
for the patient: the breast is compressed in the machine 
and the 3-D device takes a series of images through  
an arc of 15 degrees, which are then reconstructed as 
1-millimeter slices instead of just a top or side image of 
the entire breast as is done in a routine mammogram.
Philpotts calls up a 2-D image of a whole breast on 
one of two adjacent monitors. It shows a mass of white 
in the middle. Philpotts is suspicious of the mass but the 
image’s blurriness won’t let her draw any conclusions. 
She switches the display on the monitor, which then 
shows the individual images, like a high-tech zoetrope. 
Each slice shows an area deeper within the tissue. “It’s as 
if you can see through the breast,” she says. As Philpotts 
The prostate presents special problems in imaging. 
Ultrasound guides clinicians to the prostate but 
can’t image tumors, so clinicians use a combination 
of MRI and ultrasound to create a 3D model. Peter 
Schulam (standing), chair of urology, and clinician 
Preston Sprenkle discuss a case with a patient.
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needle biopsy to remove small pieces of dubious tissue. 
Ultrasound is used as a complement to mammography 
to find the extent of disease, if any, since cancerous cells 
appear dark on an ultrasound image. Patients fear a 
biopsy, but they’re relieved by the minimal invasiveness 
of the procedure.
seeing what can’t  be imaged
Improved imaging systems are also helping Yale physi-
cians treat cancers specific to men. Prostate cancer is 
even harder to find than cancer of the breast, because the 
prostate is the only solid organ in which cancer cannot 
be imaged. Ultrasound—the modality that guides clini-
cians to the prostate—alone cannot see tumors, says Peter 
Schulam, M.D., director of the Cancer Center’s Prostate 
and Urologic Cancer Program. His team, like those of 
other specialists, uses a combination of imaging modali-
ties that work better together than separately.
When Schulam arrived at Yale from UCLA last year, he 
recruited a team of doctors, engineers, and radiologists. 
He also brought a 3-D imaging navigation system called 
the Artemis Device, which he says is the best available to 
identify and monitor the progress of prostate cancer.
“Every man with prostate cancer doesn’t need to 
be treated,” Schulam says. “The question is: How 
do you differentiate?” Prostate cancer kills roughly 
30,000 American men every year—more than any 
other malignancy except lung cancer, according to the 
American Cancer Society. Most men diagnosed with the 
disease, however, die of some other cause.
High levels of prostate-specific antigen (PSA) may 
signal cancer, but an enlarged but healthy prostate can 
also raise PSA levels. In 2012, the USPSTF recommended 
against PSA screening for cancer, saying that men are too 
often treated when the disease isn’t causing symptoms. 
CT scans aren’t beneficial in detecting possible cancer, 
so doctors increasingly use MRI. “The problem is that 
once you see something suspicious on an MRI, it’s hard 
to biopsy” because the powerful magnets prevent the 
use of needles, Schulam says. A prostate biopsy is often 
educated guesswork, with doctors taking a dozen or so 
passes with a 1-millimeter-thick needle into the walnut-
sized gland. Not only are biopsies often painful proce-
dures and recovery can lead to such complications as 
sepsis, but “you can miss cancer,” Schulam says. “Or you 
can detect cancer but not know the volume of cancer.”
Because prostate cancer generally progresses very 
slowly, treatment options range from radiation or 
removal of the prostate to watchful waiting, in which 
doctors take no significant action unless the diseased 
organ causes problems. Active surveillance—careful 
monitoring for signs that the disease is progressing—is 
a relatively recent approach that falls somewhere in 
between. It is usually recommended for men at low 
risk of developing symptoms from the disease. Artemis, 
which combines MR and ultrasound images to improve 
the detection and treatment of prostate cancer, is the key 
tool in the image-guided approach to active surveillance 
of the disease.
Artemis uses a multiparametric MRI—which also mea-
sures chemical concentrations and blood flow in tissue—
to identify regions of the gland that may be cancerous. 
“The machine takes the MRI image and an ultrasound 
image and puts them together in a 3-D model,” says 
Preston Sprenkle, M.D., a urologist on Schulam’s team. 
The real-time ultrasound feature then “helps us guide 
where our needles go,” so biopsies aren’t as blind as they 
have been in the past.
The team can then determine how diseased the 
prostate is through what’s called a Gleason score—
which predicts whether the cancer will grow and 
spread to other organs—and what action comes next. 
Men with a low Gleason score can prevent or postpone 
unnecessary radiation therapy or a prostatectomy, 
which can leave patients incontinent or impotent. “If 
you lose one or both of those, your quality of life is dra-
matically changed,” Sprenkle says.
Artemis promotes active surveillance because 
it “records exactly where the biopsy was taken from,” 
Schulam says. When the team members examine the 
gland a second time, they have a superimposed image so 
“we can biopsy the exact same place as before. If some-
thing changes, you intervene such that you haven’t lost 
your window of opportunity to achieve cure.”
a revolution in  every f ield
Advances in imaging, from X-rays to CT scans to fMRI, 
have taken a lot of the guesswork out of diagnosis and 
treatment. They have reduced inaccuracies in test-
ing, spared patients anxiety from false positives, and 
improved outcomes. Spencer is happy with the progress 
he’s seen since his early days when neurosurgical imaging 
was in its infancy. “Imaging is important to everything 
we do every day,” he says. “It’s revolutionized every field. 
Our understanding of the brain—and our understanding 
of brain disease and the future of treating it—is just so 
tied to our imaging.” /yale medicine
John Dillon, a New Haven-based journalist, has been writing on 
health and medical issues for 15 years.
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 Reducing the  
risk of CT scans
For patients, computerized to-
mography (CT) scans are simple 
and painless. The machine looks 
like a big doughnut standing 
on its side. The patient lies on 
a slab that slides through the 
doughnut’s hole until the part 
of the body to be scanned is po-
sitioned beneath a rotating ring 
that contains an X-ray camera. 
Each rotation scans a “slice” of 
the body part. The patient feels 
nothing. As the camera rotates 
around the patient, the bed 
slides through the doughnut 
taking pictures. The procedure 
takes less than 10 minutes and 
generates data that a computer 
combines into a portrait of the 
area scanned, yielding images 
far superior to a shadowy two-
dimensional X-ray.
CT scans have saved count-
less lives by allowing doctors 
to detect injuries and diseases 
that don’t show up on standard 
X-rays. The scans also have 
prevented misdiagnoses and 
unnecessary surgeries. It’s not 
surprising that their use by 
doctors has surged over the 
last two decades.
  By Steve Kemper
Yet this diagnostic power 
carries a cost: Each of the rota-
tions exposes patients to doses 
of radiation that accumulate. 
Each CT scan exposes patients 
to between 100 and 500 times 
the amount of radiation in an 
X-ray. “The same doses that 
people got from the Hiroshima 
bomb drop, which we now 
know increases the risk of 
cancer development,” said Rob 
Goodman, MB BChir, interim 
chair and professor of diag-
nostic radiology and chief of 
pediatric imaging.
When Goodman came to 
Yale from Oxford in 2003, he 
was alarmed by the excessive 
use of CT scans here. Ameri-
cans were getting three times 
more medical radiation than 
were Europeans. Goodman was 
especially worried about the 
effects on children, because 
their smaller, rapidly changing 
bodies are more susceptible to 
ionizing radiation and hence to 
the risk of cancer from it.
Goodman began a campaign 
to shrink the radiation exposure 
of children who came to Yale-
New Haven Hospital (YNHH). 
He conducted grand rounds 
for pediatricians on reducing 
radiation doses and urged them 
to consider such alternatives 
to CT scans as ultrasound. He 
also worked with the hospital’s 
medical physicists to tweak the 
CT scanners to give children  
the lowest possible dose while  
still making images acceptable 
for diagnosis.
Goodman’s efforts coincided 
with a growing national aware-
ness about the risks of medical 
imaging, particularly for 
children. In January 2008 the 
Alliance for Radiation Safety in 
Pediatric Imaging, representing 
more than 70 medical organi-
zations, launched the Image 
Gently campaign to educate 
doctors and the public about 
cumulative radiation exposure. 
Manufacturers began building 
scanners that automatically 
adjusted the dose based on 
the patient’s age and weight, 
as well as the sensitivity of the 
area to be scanned. 
These steps have raised 
consciousness and lowered 
CT use, but children are still 
getting too much radiation. In 
June, a study published in JAMA 
Pediatrics reported that of the 
estimated 4 million CT scans 
given every year to children 
in the United States under 
age 15, a third are unneces-
sary and may lead to 5,000 
cases of cancer. In the same 
month, a study published in The 
Lancet found that children who 
get multiple CT scans have a 
slightly higher risk of develop-
ing leukemia or brain cancer.
At YNHH, Goodman’s efforts 
have paid off. In data compiled 
by the American College of Ra-
diology’s Dose Index Registry, 
which tracks and categorizes 
the radiation given by CT scan-
ners in U.S. hospitals, YNHH 
recorded the lowest doses of 
any hospital in the country in 
many age groups and types of 
pediatric CT studies.
The hospital’s own statistics 
tell a similar story. In 2003 
YNHH had three CT scanners 
and did 4,844 CT scans on 
children. In 2012, despite now 
having seven scanners, the 
hospital did only 2,344 studies 
on children. Those numbers 
took even Goodman by surprise.
Goodman expects the 
numbers to drop further as 
MRI, which emits no radiation, 
replaces CT scans for many di-
agnoses. His campaign to lower 
radiation doses at YNHH has 
been so successful that he now 
sometimes finds himself urging 
clinicians and parents not to 
avoid CT scans in the correct 
clinical setting. “If the suspicion 
is high that your child may have 
a significant lesion in the lung,” 
he said, “be reassured that the 
CT radiation doses at Yale are 
the lowest in the country and 
doing the scan is what’s best 
for the patient.”
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 Brain imaging in  
the era of bell bottoms
“We are proposing that the 
Yale-New Haven Hospital 
acquire the EMI scanner, 
[which] represents the most 
revolutionary advance in 
neuroradiologic evaluation 
of patients. …” So begins the 
December 1973 letter from 
E. Leon Kier, M.D., HS ’66, 
that would lead to Yale-New 
Haven Hospital’s acquisi-
tion of Connecticut’s first 
computed tomography (CT) 
scanner. The first-of-its-
kind scanner that Kier refers 
to in the letter was named 
after the company where 
it was developed, the EMI 
record label, which also had 
an independent electrical 
and computer engineering 
arm. (Profits generated by 
the British label’s top artists—
four young Liverpudlians 
named John, Paul, George, 
and Ringo—supported 
EMI’s investment in the CT 
machine.) Kier, then chief 
of neuroradiology, was 
writing to the chair of the 
diagnostic radiology depart-
ment, Richard H. Greenspan, 
M.D., to convince him of the 
necessity of acquiring the 
new machine, which was 
first used on human patients 
in October 1971 in England.
In the early 1970s, there 
were two main methods for 
diagnosing patients with 
neurological problems: cere-
bral angiography and pneu-
moencephalography. The 
resulting images could tell a 
well-trained viewer what part 
of the brain was affected and 
whether the lesion in question 
was a tumor, vascular malfor-
mation, or hematoma (bleed-
ing). “These procedures were 
time-consuming and risky for 
the patient and required hos-
pitalization,” Kier says today.
If a patient came into 
the emergency room with a 
stroke, angiography would 
be performed: A catheter 
was inserted into a large 
artery and threaded from the 
neck to the carotid, where a 
contrast agent was injected. 
Radiographs taken while 
the contrast agent circulated 
would help identify the 
location of constriction or 
 Arrival of the CT scanner at Yale
  By Amanda Alvarez
bleeding. During a pneumo-
encephalogram, oxygen 
was injected into the spinal 
subarachnoid space (a cav-
ity filled with cerebrospinal 
fluid that contains the blood 
vessels that supply the brain 
and spinal cord), which per-
mitted the visualization of 
the brain’s ventricular sys-
tem and subarachnoid spaces 
on X-rays. Kier recalls that 
these procedures were dan-
gerous for the patients if not 
done properly.
Compared to these meth-
ods, Kier says, CT was “a 
quantum jump. It was a revo-
lutionary development, and 
we felt that we had to get the 
machine to move into a whole 
new phase of medical care.” 
The scanner that was acquired 
was actually the ACTA, a 
CT scanner developed at 
Georgetown University whose 
gantry size allowed imaging 
of the whole body, not just the 
head, as with the EMI scanner. 
There was a research scanner 
on campus as early as 1972, 
and this was used to image 
both healthy volunteers and 
patients with trauma. Because 
it wasn’t yet known whether 
CT images were sufficient or 
useful for diagnosis, these 
initial studies helped justify 
the clinical protocol and need 
for a dedicated CT scanner 
for patient care. By 1978, the 
CT facility at the hospital 
was open 24 hours a day, and 
by 1990, when Kier stepped 
down as chief of neuroradiol-
ogy, there were four scanners.
Kier’s radiology tech-
nologist at the time, Cathy 
Camputaro, recounted the 
early CT scanning procedure. 
“Imaging the head from the 
bottom of the chin to the 
crown took an hour, or six 
minutes per image slice. Now 
the entire body can be done 
in 14 seconds.” Patients were 
sent away while computers 
reconstructed the images, 
which were then printed as 
Polaroids or on X-ray film. 
“When the first images came 
out, I was stunned that I 
could see the ventricles. It 
was incredible. There was no 
other way at that time to do 
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neurological diagnoses except 
with cerebral angiography or 
pneumoencephalography.” 
Camputaro, who still man-
ages 3-D CT and MR imaging 
at the hospital, says that not 
only did CT simplify image 
interpretation, but it also 
changed how anatomy and 
physiology are taught. Since 
almost all ER patients are 
automatically scanned, and 
those scans are available on 
the hospital server, students 
are now trained with CT 
images rather than with text-
book images.
Summing up the sea 
change, Kier, who is still one 
of the hospital neuroradiolo-
gists, says, “We went from 
painful, dangerous proce-
dures to painless and safe 
procedures. Of all the changes 
that the diagnosis of neu-
rological disorders has gone 
through prior to the modern 
era of MRI scanning, the big-
gest change was at the time 
CT was introduced.”
OPPOSITE Side-by-side 
images of a CT scan 
from the 1970s and a 
more recent scan show 
how the technology has 
advanced.
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“I don’t think my dad really understood labor laws,” said Abrahimi with 
a laugh. During the week, his father did odd jobs, and the family lived 
in public housing.
In a roundabout way, it was that flea market that set Parwiz Abrahimi 
on the road to what he is today: an M.D./Ph.D. student at Yale and a 2013 
recipient of a Paul & Daisy Soros Fellowship for New Americans. 
Abrahimi and his family came to the United States from Afghanistan 
in 1990, when he was four. Fighting against the invading Soviet army 
had turned into a civil war a year earlier after the Soviet Union withdrew 
its troops from the country. Three of Abrahimi’s uncles had died in the 
violence, and his father, who had worked for the previous government, 
had twice been arrested. A smuggler led the family—members of the per-
secuted minority group, the Hazara—through the mountains to Pakistan. 
They were granted asylum in the United States 18 months later.
When Abrahimi was 12, his father bought him a manual for the 
programming language C++ at the swap meet. As Abrahimi struggled 
to learn the program on a clunky Intel “286,” he discovered that “I was 
a technical guy.” It opened up the world of quantitative reasoning. The 
gift also conveyed a message: that learning was a priority. “We took 
the interpretation of the American dream as obtaining an education 
and achieving social mobility.”
At the University of Washington, Abrahimi studied biomedical 
engineering because it was new and multidisciplinary and addressed 
problems in medicine. He graduated in 2007 and worked for a year at 
the National Institute on Aging in Baltimore, Md., trying his hand at 
laboratory research “to see if it was something for me.” It was.
In 2008, before starting the M.D./Ph.D. program, Abrahimi taught sci-
ence for a year at the American University of Afghanistan in Kabul and at 
Marefat High School in his family’s former home, the impoverished Dashti 
 From selling used car parts 
to studying organ transplants
»
F ROM T H E T I M E PA RW I Z A B R A H I M I S TA RT E D S C HO OL until he was 
13 or 14, weekend mornings often meant getting up at 1 a.m. to help his 
father deliver The Seattle Times. Then, before sunrise, Parwiz and his 
brother and two sisters would help their parents load used car parts into  
a rickety station wagon to sell what they could at the Midway Swap & 
Shop in suburban Seattle.
A former refugee from 
Afghanistan finds hope in 
the American dream and 
















Barchi neighborhood. He moved 
to New Haven a year later to 
begin his medical studies. Three 
years later, before beginning his 
doctoral research, he returned to 
Afghanistan to study the safety of 
donated blood.
Now doing his doctoral 
research in the laboratory 
of Jordan S. Pober, M.D. ’77, 
Ph.D. ’77, professor of immu-
nobiology, Abrahimi is testing 
ways to modify foreign proteins 
in a transplanted organ so that 
received one of 30 fellowships, 
which provide $90,000 over two 
years to fund living expenses 
and tuition. Fellowship direc-
tor Stanley J. Heginbotham said 
that Abrahimi stood out for his 
achievements in academia and 
for “his commitment to moral 
solutions in Afghanistan, and his 
commitment to transplant medi-
cine. … This guy’s going to make a 
real difference in some aspect of 
American life.”
In his spare time Abrahimi 
serves as a director for social ser-
vices at the student-run HAVEN 
Free Clinic in New Haven. He 
envisions a career that combines 
care of transplant patients with 
»
Patience pays off for  
Yale neuroscientist- 
turned-inventor
Medical students who’ve stud-
ied on an iPhone while wait-
ing in line for a latte have Mark 
Williams, Ph.D. ’96, to thank 
for helping break the chains that 
once bound them to the library.
After completing his Ph.D. 
in neuroscience at the School 
of Medicine and postdoctoral 
research at Duke University, 
Williams found that basic sci-
ence research wasn’t for him. 
With interests spanning neuro-
anatomy, art, design, communi-
cations, and business, he asked, 
“What’s a career that you can 
build from that?”
Somewhere between the 
time that a computer cropped 
up in every home and a smart-
phone appeared in every pocket, 
Williams found the answer. 
He first developed educational 
materials on CD-ROM for medi-
cal students in the late-1990s. 
Eventually he was designing apps 
for the video iPod before there 
was a way for consumers to buy 
such apps. In 2008, when Apple 
launched the App Store—the 
platform through which iPod 
touch and iPhone users now buy 
software—four of Williams’ prod-
ucts were among the first 500. 
Williams’ company, Modality, 
produced two Frommer’s travel 
guides, Netter’s Anatomy Flash 
Cards and Netter’s Neuroscience 
Flash Cards.
Williams’ inspiration came 
when he started teaching neuro-
science to first-year med students 
   Parwiz Abrahimi // 
  “This is a country that took my  
 family in when we had nothing,  
   and here I am studying at Yale.’’research on transplantation. “My end goal is to become a physician- 
scientist, for the clinical care to 
inform my research.”
Abrahimi became a U.S. citi-
zen in 1997. “This is a country 
that took my family in when 
we had nothing, and here I am 
studying at Yale,” he said. “That 
said a lot about the country, that 
it would provide an opportunity 
to a person like me. This is a 
country of immigrants, and my 
generation of Afghan Americans 
is slowly being integrated into 
this country and is able to con-
tribute back to the society.”
—Cathy Shufro
they won’t set off alarm bells in 
the recipient’s immune system. 
Those warning proteins come 
from the endothelium, the thin 
layer of cells that lines blood 
vessels in the organ.
“We want to change the gene 
expression of the endothelium 
to make it less stimulating to the 
immune system,” said Abrahimi. 
While most efforts to prevent 
rejection focus on dampening 
the host’s immune response, 
Abrahimi is looking at modifying 
the transplanted organ.
Pober describes Abrahimi’s 
ability to design and carry out 
experiments as “remarkably 
well-developed for someone this 
early in their graduate training.”
In May the Soros Fellowship 
announced that Abrahimi had 
yalemedicine.yale.edu46
faces
at Duke in 1997. He wanted to 
tackle an educational challenge. 
“How could we reinforce the basic 
concepts outside the classroom 
so that class time is really about 
problem-solving, collabora-
tion, and building relationships 
between student and mentor?”
In the late 1990s, at a time 
when every textbook came 
with a supplemental CD-ROM, 
Williams developed a neuro-
anatomy reference on CD-ROM 
through startup company 
Pyramis. Users could select 
the name of a part of the brain, 
see images of it, then slice it 
and rotate it in 3-D. “It’s silly 
today, but the Internet was only 
just emerging. This was a great 
way to see an image and learn 
where it’s located in the brain,” 
Williams said.
Williams left Duke in 2005 to 
focus on software development 
and to start a company which 
eventually became Modality. He 
remains in Chapel Hill, where 
he continues to develop new 
technologies.
As personal technology moved 
from the desktop to the palm of 
the hand, so did Modality.
When the market shifted 
toward digital flashcards, text-
books, and guides, Williams 
and his team learned to trans-
form already digitized content 
into applications for handheld 
devices. They could format any 
digital book for use on an iPod. 
The only problem was that Apple 
did not allow software develop-
ment for the iPod at this time. 
Williams and his team waited 
to cross-reference images in 
countless anatomy atlases with 
their own CT and MR images. 
“Clinicians saw the value of 
having their device in the clinic 
and showing the anatomy to a 
patient. It was a real opportu-
nity for patient engagement.”
In 2012, shortly after 
Epocrates bought the company, 
Williams left Modality to pursue 
projects on his own. He wants 
to develop apps to maximize 
relationship-building opportu-
nities for patients and doctors 
the way his educational software 
does for students and teachers. 
“Technology should be clearing 
the way for these relationships 
to take hold,” he said.
—Sonya Collins
for a day when Apple would rec-
ognize their worth.
“That day came. We got the 
call,” Williams said. They made 
a deal for Modality to sell its 
products to video iPod users.
This was in 2007, when users 
had to go to an Apple store—in 
person—to buy a code on a card 
so they could download the app 
to their computers and trans-
fer it to their iPods. Droves of 
publishers clamored to get onto 
the gizmos that their campus 
reps were seeing plugged into 
the ears of college students 
everywhere.
Modality transformed a 
number of titles, but Williams 
was most excited about medical 
illustrator Frank Netter’s prod-
ucts, which are published by 
Elsevier. “Netter revolutionized 
medical illustration, so when we 
could bring that to the iPod, it 
was really exciting,” he said.
The users were fans, too.
“A student said to me, ‘Dr. 
Williams, I learned five new 
brain terms while I was waiting 
in line for my latte today.’ ”
In 2008, at the Apple World-
wide Developers Conference, 
former Apple CEO Steve Jobs 
announced the launch of the 
App Store, which allowed users 
to download apps directly from 
their phones. Onstage beside him 
were the dozen developers whose 
products would stock the store. 
Among them was Williams.
Over the next two years, 
Modality launched more than 
150 educational apps, includ-
ing one that allowed users 
An alumnus was building 
educational apps for the 
iPod before Apple was 
ready for him. The com-
pany finally saw the light.
A project to build over 
the Route 34 Connec-
tor reverses an urban 
renewal project of the 
1960s and vies to bring 
two parts of the city 
together.
Humility was the word 
of the day at the Com-
mencement Ceremony 
held May 21 for the 
91 members of the  
Class of 2013.
An impressive 32 mem-
bers of the Class of 1963, 
along with their guests, 
celebrated their 50th 
Reunion at the Quin-
nipiac Club on June 1!
A new scholarship  
gives aspiring surgeons 
a boost.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 

























How did you get into a 
profession that didn’t exist 
when you were born?  
I first learned about the field 
of genetic counseling when 
I was a sophomore at Union 
College, taking a course 
in genetics. I enjoyed the 
course so much that I did an 
internship at Albany Medical 
School. At that time, cancer 
genetics was not an option 
because the field hadn’t 
even cracked open yet. My 
first job out of graduate 
school was doing pediatric 
and adult genetics at SUNY 
Upstate Medical Center in 
New York. It was then, in 
1995, that significant discov-
eries began being made in 
cancer genetics.
What has changed since 
you started? When the 
genetic counseling pro-
gram was started in 1995 
by Vincent DeVita, who 
was director of Yale Cancer 
Center, I was everything.  
I was the secretary;  
I scheduled appointments. 
They gave me a supply closet 
that they had emptied out  
for my office. Now we have 
two secretaries, a phle-
botomist, and six and a half 
genetic counselors, and we 
are still growing.
In 1995, BRCA1 and 
BRCA2 hadn’t been cloned, 
so we didn’t have genetic 
testing for that condition. 
Patients would come in, 
 Ellen Matloff was right— 
the Supreme Court said so
watch an interview 




ON J U N E 13,  2013, in the case of the Association for Molecular Pathology 
v. Myriad Genetics, the United States Supreme Court ruled, in a unani-
mous decision, that genes cannot be patented. The news was both a shock 
and a relief to Ellen T. Matloff, M.S., who started Yale’s Cancer Genetic 
Counseling Program in 1995. For 14 years Matloff had argued that some-
thing occurring in nature should not merit patent protection and that 
the patents were harming patients and medical researchers. When the 
American Civil Liberties Union filed a suit against Myriad Genetics, which 
held patents on the BRCA1 and BRCA2 genes that are linked to breast and 
ovarian cancers, Matloff joined the case as a plaintiff. Two weeks after the 
Supreme Court decision, Matloff spoke with Yale Medicine.
{To nominate a subject for Q&A, contactYale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or e-mail ymm@yale.edu
we’d take their family his-
tory, and determine, based 
on that history, if it looked 
hereditary. If it did, we 
would make estimates of 
their risk to develop cancer. 
I’d been at Yale for about 
three months when BRCA 
testing became available 
and the phones were ringing 
off the hook. With BRCA1 
and BRCA2, genetic testing 
really became available to 
the masses.
With her decision to go 
public on her double mas-
tectomy, has Angelina Jolie 
done a service to the cause 
of genetic counseling? For 
a movie star whose liv-
ing is based on her body 
and her looks, as well as 
her talent, to put this out 
there was a really brave 
thing to do. Since the story 
broke, our referral rate has 
increased by 40 percent. A 
lot of people have asked me 
if Angelina Jolie made the 
right choice. This is a very 
individual decision. It var-
ies based on the person, the 
family history, and personal 
preferences. Do I think 
Angelina Jolie made a rea-
sonable decision? Absolutely. 
She’s reduced her risks 
tremendously. She’s reduced 
her worry.
How did you get involved in 
the Myriad case? I’d been 
very outspoken about the 
danger of gene patenting 
since the late 1990s. I had 
written many editorials to 
prestigious medical journals 
and they told me my letter 
was so preposterous they 
weren’t even going to send it 
out for review. I couldn’t get 
anyone to take it seriously. 
Someone suggested I contact 
a very well-known bioethi-
cist, Arthur Caplan, and see 
if I could get him interested 
in becoming a co-author. Lo 
and behold, he was inter-
ested. Because of his reputa-
tion, we landed the cover of a 
prestigious bioethics medical 
journal. Later on, when the 
ACLU decided to sue and was 
looking for plaintiffs, I got a 
phone call.
Why shouldn’t genes be pat-
ented? First of all, patents 
are supposed to be protection 
for innovation. The human 
gene is nothing that was dis-
covered by Myriad Genetics. 
There was nothing new 
invented. Second, we can 
now see what kind of dam-
age can be done to patients 
and researchers if a company 
holds the patent to the letter 
of the law. When BRCA1 and 
BRCA2 were first discovered, 
there were many labs across 
the country that were offer-
ing testing. We were offer-
ing testing here at Yale for 
$1,600. Over time the cost 
of genetic testing has gone 
down, down, down, yet the 
cost of BRCA testing went up, 
up, up. Before the patent was 
overturned, the cost of BRCA 
testing was $4,000.
Where were you when you 
heard the Supreme Court 
decision? The decision came 
on my daughter’s last day 
in preschool, and I went for 
the parent sing-along. It was 
pouring rain. We ran from 
preschool to the car and 
were soaking wet. It was 
then that I heard my cell 
phone going crazy. I had a 
million text messages, and 
they all said the same thing: 
unanimous decision by the 
Supreme Court banning gene 
patents. I started crying. I 
was shocked and relieved 
and overwhelmed. For me 
this had been a 14-year bat-
tle. To have it go all the way 
to the Supreme Court and to 
have it be a unanimous deci-
sion were just overwhelm-
ing. My 3-year-old daughter 
was alarmed that mommy 
was crying. I said, “We won 
today. These are happy tears.”


















 What should  
we believe?
News about health deluges us 
daily: On the nightly news, 
in the newspaper, on blogs, 
and even at parties, we hear 
pronouncements about what 
to eat, what pill to take, 
which screening test we 
absolutely must schedule—or 
might be better off avoiding. 
And what’s recommended 
one day seems laughable 
the next. So what health 
news should we heed? What 
should we ignore?
Most of us lack the 
tools to judge, said Michael 
B. Bracken, M.P.H. ’70, 
Ph.D. ’74, the Susan 
Dwight Bliss Professor of 
Epidemiology at the School 
of Public Health. “We don’t 
educate children and adults 
in anything to do with 
understanding risk or prob-
ability,” Bracken said in a 
recent interview.
Bracken offers a rem-
edy in his new book, Risk, 
Chance, and Causation: 
Investigating the Origins 
and Treatment of Disease. 
In this accessible, lively, and 
often witty book, Bracken 
explains how epidemiolo-
gists understand the world. 
He shows why good study 
design is crucial in distin-
guishing between chance 
and causation. Bracken dis-
cusses the reasoning behind 
ethical guidelines and, 
surprisingly, explains how 
they can sometimes cause 
harm. In “Celebrity Trumps 
Science,” Bracken cites a 
rock star’s misinformation 
about the effects of mari-
juana and an ex-Playboy 
bunny’s inaccuracies about 
the cause of autism.
In addition, Bracken 
devotes a chapter to the 
benefits and the limita-
tions of using animals for 
research—animals often fail 
as proxies for human beings. 
For example, a potential 
leukemia drug worked well 
in monkeys but nearly killed 
six healthy humans.
Bracken lays out the 
principles of a good study by 
describing one from China 
that tested whether women 
who examined their breasts 
for lumps reduced their 
chance of dying from breast 
cancer. The study enlisted 
250,000 women and com-
pared a study group (women 
taught self-examination) 
with a control group (women 
not instructed in self-exam). 
All were Shanghai textile 
workers living similar life-
styles, which minimized 
influences of other variables. 
The 10-year study found 
that the women trained in 
self-exam found more breast 
lumps than the controls did, 
but deaths from breast cancer 
were identical in both groups.
An example from 
Bracken’s own research on 
the effects of early child-
hood illness on later chronic 
disease illustrates the 
complexity of study design. 
Does giving antibiotics to 
very young children make 
them more likely to develop 
asthma? Antibiotics might 
limit the development of the 
child’s immune system. On 
the other hand, children 
prone to asthma may get 
more antibiotics because 
they wheeze. Even care-
ful study design could not 
totally eliminate uncertain-
ties about which came first: 
the antibiotics or the asthma.
The deluge of health 
news will remain relentless, 
he said. “The 24-hour news 
cycle has to be continually 
fed. They jump on every-
thing.” Unless people learn 
how to evaluate news on their 
own, he said, “the net effect 
will be that the real health 
messages get lost in this 
quagmire of misinformation.” 
  In a new book, a public health  
professor helps the public understand what’s  
 behind health reports in the media.
















































{Send notices of new books toYale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or e-mail ymm@yale.edu
book review
DU R I NG A W E E K I N J U N E visitors to the Yale School of Art’s Green Gallery were treated to 
glass representations of the human anatomy, everything from wombs to gall bladders includ-
ing this depiction of human fat. The exhibit, “Looking In,” was assembled by physicians, glass 
artists, and Reintegrate: Enhancing Collaborations in the Arts and Sciences and coincided with 
New Haven’s annual International Festival of Arts & Ideas. 
The exhibit closed with a talk by David Yuh, M.D., professor and chief of cardiac surgery at 
the School of Medicine, a member of the doctor/artist team. Others on the team included medi-
cal student Lucinda Liu; G. Kenneth Haines III, M.D., associate professor of pathology; and glass 
artists Michael Skrtic and Daryl Smith, a scientific glassblower in Yale’s chemistry department. 
Sinclaire Marber, a student at Yale College, curated the exhibit.
—John Curtis
Art and the human body
end note
